

# CITATION REPORT

List of articles citing

## Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

DOI: 10.1056/nejmoa1507643

New England Journal of Medicine, 2015, 373, 1627-39.

**Source:** <https://exaly.com/paper-pdf/62404990/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2246	Current state of immunotherapy for non-small cell lung cancer. <b>2017</b> , 6, 196-211		107
2245	Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. <b>2017</b> , 6, 178-185		16
2244	Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. <b>2017</b> , 6, 169-177		2
2243	Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors. <b>2017</b> , 6, 186-195		8
2242	Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. <b>2017</b> , 6, 220-229		9
2241	Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART). <b>2017</b> , 6, 159-168		24
2240	Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. <b>2017</b> , 6, 113-118		11
2239	Special topics in immunotherapy and radiation therapy: reirradiation and palliation. <b>2017</b> , 6, 119-130		10
2238	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. <b>2015</b> , 17, 1020-9		37
2237	Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future. <b>2015</b> , 3, 360-381		32
2236	Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells. <b>2015</b> , 6, 633		9
2235	Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies. <b>2015</b> , 3, 1292-8		21
2234	Immunotherapy: the third wave in lung cancer treatment. <b>2015</b> , 3, 923-4		2
2233	Nivolumab--an effective second-line treatment for NSCLC. <b>2015</b> , 12, 685		4
2232	Nivolumab: a review in advanced squamous non-small cell lung cancer. <b>2015</b> , 75, 1925-34		16
2231	[Nivolumab, a new hope in non-small cell lung cancer]. <b>2015</b> , 102, 1046-52		2
2230	Nivolumab for treating non-small cell lung cancer. <b>2015</b> , 15, 1789-97		19

2229	Developing an Immunotherapy Strategy for the Effective Treatment of Oral, Head and Neck Squamous Cell Carcinoma. <b>2015</b> , 73, S107-15	3
2228	Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. <b>2015</b> , 41, 868-76	280
2227	Battling regional (stage III) lung cancer: bumpy road of a cancer survivor in the immunotherapy age. <b>2016</b> , 2016,	1
2226	The Paradox of Anti-cancer Agents and Recurring Emergence of Drug Resistance. <b>2016</b> , 05,	
2225	Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches. <b>2016</b> , 8, E1348-E1350	
2224	Immuno-oncology. <b>2016</b> ,	
2223	Immuntherapie bei Lungenkrebs. <b>2016</b> , 3, 60-68	
2222	Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. <b>2016</b> , 7, 56233-56240	43
2221	Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. <b>2016</b> , 9, 6075-6082	40
2220	Immuno-oncology combinations: raising the tail of the survival curve. <b>2016</b> , 13, 171-93	67
2219	Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. <b>2016</b> , 7, 52810-52817	250
2218	Contemporary Treatment of Metastatic Renal Cell Carcinoma. <b>2016</b> , 10, 295	29
2217	Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. <b>2016</b> , 7, 32113-28	81
2216	Immune checkpoint inhibition in patients with brain metastases. <b>2016</b> , 4, S9	27
2215	Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. <b>2016</b> , 9, 5855-5866	8
2214	Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?. <b>2016</b> , 10, 293	38
2213	Aptamers: A promising chemical antibody for cancer therapy. <b>2016</b> , 7, 13446-63	63
2212	Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?. <b>2016</b> , 13, 157-70	60

2211	Targeted therapies and immunotherapy in non-small-cell lung cancer. <b>2016</b> , 10, 648	20
2210	Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings. <b>2017</b> , 10, 153-163	19
2209	-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. <b>2017</b> , 10, 101-112	43
2208	Combined modality therapy for thoracic and head and neck cancers: a review of updated literature based on a consensus meeting. <b>2016</b> , 102, 459-471	8
2207	Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. <b>2016</b> , 9, 3187-95	11
2206	New targeted treatments for non-small-cell lung cancer - role of nivolumab. <b>2016</b> , 10, 103-17	18
2205	Lung cancer in Brazil: epidemiology and treatment challenges. <b>2016</b> , 7, 141-148	10
2204	Pneumonitis with Nonspecific Interstitial Pneumonia Pattern Caused by Nivolumab in a Patient with Metastatic Melanoma. <b>2016</b> , 06,	
2203	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability . PD-L1. <b>2016</b> , 7, 771-788	61
2202	Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer. <b>2016</b> , 7, 20282-92	19
2201	Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies. <b>2016</b> , 35, e175-84	8
2200	Biomarkers for Immunotherapy: Current Developments and Challenges. <b>2016</b> , 35, e493-503	61
2199	Immunotherapy for Soft Tissue Sarcoma: Tomorrow Is Only a Day Away. <b>2016</b> , 35, 281-90	8
2198	PD-L1 expression in lung cancer. <b>2016</b> , 8, 3053-3055	1
2197	Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. <b>2016</b> , 5, 628-636	12
2196	Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?. <b>2016</b> , 5, 538-542	4
2195	Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. <b>2016</b> , 5, 720-726	24
2194	Non-Small-Cell Lung Cancer Treatment. <b>2016</b> , 62, 7-12	1

2193	Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. <b>2016</b> , 5, 301-21	33
2192	The role of surgical intervention in lung cancer with carcinomatous pleuritis. <b>2016</b> , 8, S901-S907	7
2191	Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer. <b>2016</b> , 8, E1254-E1256	
2190	Pathophysiologie der Entzündung. <b>2016</b> , 55, 1-6	4
2189	Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy. <b>2016</b> , 24, 7	3
2188	Drugs That Act on the Immune System. <b>2016</b> , 395-405	1
2187	Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. <b>2016</b> , 7, 77404-77415	115
2186	Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer. <b>2016</b> , 2016, 3494608	24
2185	A Case of Non-Small Cell Lung Cancer with Possible "Disease Flare" on Nivolumab Treatment. <b>2016</b> , 2016, 1075641	20
2184	PD-1 blockade enhances the vaccination-induced immune response in glioma. <b>2016</b> , 1,	103
2183	Potential role of immunotherapy in advanced non-small-cell lung cancer. <b>2017</b> , 10, 21-30	33
2182	PharmaForum. <b>2016</b> , 39, 401-404	
2181	High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. <b>2016</b> , 6, 1629-40	138
2180	High-grade glioma management and response assessment-recent advances and current challenges. <b>2016</b> , 23, e383-91	25
2179	Neither the maximum tumor size nor solid component size is prognostic in part-solid lung cancer: to be ground-glass opacity or not to be, is that really the question?. <b>2016</b> , 8, 2334-2336	3
2178	Non-small cell lung cancer: current treatment and future advances. <b>2016</b> , 5, 288-300	762
2177	Improving the efficiency of image guided brachytherapy in cervical cancer. <b>2016</b> , 8, 557-565	11
2176	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. <b>2016</b> , 7, 550	282

2175	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. <b>2016</b> , 7, 621	90
2174	Focus on Alectinib and Competitor Compounds for Second-Line Therapy in -Rearranged NSCLC. <b>2016</b> , 3, 65	4
2173	Focus on Nivolumab in NSCLC. <b>2016</b> , 3, 67	3
2172	Are We Making Personalized Cancer Care Less Personalized?. <b>2016</b> , 6, 220	
2171	Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. <b>2016</b> , 6, 233	94
2170	Recent Advances in Immunotherapy in Metastatic NSCLC. <b>2016</b> , 6, 239	23
2169	Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma. <b>2016</b> , 8,	21
2168	Advances in Cancer Immunotherapy in Solid Tumors. <b>2016</b> , 8,	109
2167	The Utilization of the Immune System in Lung Cancer Treatment: Beyond Chemotherapy. <b>2016</b> , 17, 286	4
2166	Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. <b>2016</b> , 17,	41
2165	Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. <b>2016</b> , 4, 13	131
2164	PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis. <b>2016</b> , 11, e0160485	25
2163	Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. <b>2016</b> , 10, 3153-3161	19
2162	The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials. <b>2016</b> , 9, 5867-5874	14
2161	PD-L1 expression in human cancers and its association with clinical outcomes. <b>2016</b> , 9, 5023-39	370
2160	Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. <b>2016</b> , 9, 5101-16	26
2159	Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. <b>2016</b> , 9, 3711-26	71
2158	Aptamers: A New Technological Platform in Cancer Immunotherapy. <b>2016</b> , 9,	17

2157	The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. <b>2016</b> , 7, 74350-74361	31
2156	The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. <b>2016</b> , 4, 215	6
2155	Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. <b>2016</b> , 4, 268	13
2154	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. <b>2016</b> , 7, 73068-73079	60
2153	Immune Checkpoint Therapy in Head and Neck Cancers. <b>2016</b> , 22, 108-16	10
2152	Chemoradiotherapy of locally advanced nonsmall cell lung cancer: state of the art and perspectives. <b>2016</b> , 28, 104-9	13
2151	Adjuvant therapy for nonsmall cell lung cancer: recent advances and future perspectives. <b>2016</b> , 28, 150-8	5
2150	Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. <b>2016</b> , 98, 114-117	99
2149	Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer. <b>2016</b> , 21, 974-80	52
2148	Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies. <b>2016</b> , 8, 809-19	39
2147	Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. <b>2016</b> , 8, 821-37	96
2146	Immunothérapie : un nouveau paradigme dans la prise en charge du cancer bronchique non ^ petites cellules. <b>2016</b> , 18, 365-370	1
2145	Place des antiangiogéniques dans le traitement des cancers du poumon. <b>2016</b> , 18, 409-418	1
2144	Immune Checkpoint Therapy in Non-Small Cell Lung Cancer. <b>2016</b> , 22, 81-91	7
2143	Immune Checkpoint Therapy and the Search for Predictive Biomarkers. <b>2016</b> , 22, 68-72	26
2142	Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. <b>2016</b> , 98, 51-58	81
2141	Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors. <b>2016</b> , 40, 1133-42	62
2140	Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. <b>2016</b> , 34, 596-603	35

2139	Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. <b>2016</b> , 129, 453-460	61
2138	Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. <b>2016</b> , 28, 254-63	157
2137	Wnt/ $\beta$ -catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights. <b>2016</b> , 49, 1-12	63
2136	Evolving Landscape of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <b>2016</b> , 34, 3233-4	
2135	Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. <b>2016</b> , 8, 1079-85	124
2134	Irradiation and immunotherapy: From concept to the clinic. <b>2016</b> , 122, 1659-71	55
2133	Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy. <b>2016</b> , 100, 220-2	17
2132	Immune-mediated respiratory adverse events of checkpoint inhibitors. <b>2016</b> , 28, 269-77	33
2131	Rare side-effects of checkpoint inhibitors. <b>2016</b> , 28, 295-305	6
2130	Chemotherapy-sparing treatment strategies for follicular lymphoma: current options and future directions. <b>2016</b> , 23, 371-6	
2129	Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <b>2016</b> , 34, 2969-79	322
2128	Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <b>2016</b> , 34, 2980-7	338
2127	Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer. <b>2016</b> , 34, 2953-5	11
2126	Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab. <b>2016</b> , 99, 123-6	35
2125	Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. <b>2016</b> , 29, 1165-72	269
2124	Immune checkpoint inhibitors side effects and management. <b>2016</b> , 8, 799-807	42
2123	Immune Checkpoint Therapies in Prostate Cancer. <b>2016</b> , 22, 117-20	34
2122	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. <b>2016</b> , 115, 252-60	51



2121	Immunotherapy for genitourinary cancer: state of the art and new perspectives. <b>2016</b> , 27, 585-99	4
2120	The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy. <b>2016</b> , 100, 212-4	19
2119	Immune-Related Adverse Events From Immune Checkpoint Inhibitors. <b>2016</b> , 100, 242-51	66
2118	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. <b>2016</b> , 14, 255-64	272
2117	AACR Cancer Progress Report 2016. <b>2016</b> , 22 Suppl 19, S1-S137	27
2116	Predictive biomarkers for checkpoint inhibitor-based immunotherapy. <b>2016</b> , 17, e542-e551	842
2115	Neurological sequelae of cancer immunotherapies and targeted therapies. <b>2016</b> , 17, e529-e541	59
2114	Les inhibiteurs des points de contrôle immunitaire dans le cancer bronchique non à petites cellules de stade avancé. <b>2016</b> , 103 Suppl 1, S138-S143	0
2113	Biomarqueurs prédictifs de réponse aux traitements bloquant les voies de costimulation inhibitrices. <b>2016</b> , 103 Suppl 1, S151-S159	4
2112	Performance Status-Based Oncology Practice Guidelines: Easier Said Than Done. <b>2016</b> , 12, 597-9	
2111	Immunotherapy for Lung Cancer. <b>2016</b> , 39, 360-8	9
2110	Cancer immunotherapy trials: leading a paradigm shift in drug development. <b>2016</b> , 4, 42	28
2109	Biochemistry of Oxidative Stress. <b>2016</b> ,	3
2108	Overview and management of toxicities of immune checkpoint-blocking drugs. <b>2016</b> , 7, 28-37	1
2107	Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors. <b>2016</b> , 1, e000083	45
2106	Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis. <b>2016</b> , 15, 67	96
2105	What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO). <b>2016</b> , 4,	78
2104	A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity. <b>2016</b> , 1, 16025	25

2103	Nivolumab-associated acute glomerulonephritis: a case report and literature review. <b>2016</b> , 17, 188	75
2102	Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know. <b>2016</b> , 8, 1437-1446	19
2101	Immune checkpoint inhibitors renal side effects and management. <b>2016</b> , 8, 1417-1425	8
2100	Renal effects of immune checkpoint inhibitors. <b>2017</b> , 32, 936-942	48
2099	Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis. <b>2016</b> , 11, 2048-2050	34
2098	Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease. <b>2016</b> , 5, e109	22
2097	Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. <b>2016</b> , 6, 31726	169
2096	Emerging therapeutic agents for lung cancer. <b>2016</b> , 9, 138	65
2095	MicroRNA-profiles in lung adenocarcinomas. <b>2016</b> , 1, 469-474	
2094	Colite induite par les inhibiteurs de checkpoint immunitaire : anticorps anti-CTLA-4 et anticorps anti-PD-1/PDL-1. <b>2016</b> , 18, 501-508	1
2093	Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. <b>2016</b> , 14, 173	77
2092	Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer. <b>2016</b> , 10, 336-342	8
2091	A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer. <b>2016</b> , 95, e5539	30
2090	Rationale of an economically driven PD1 biomarker development in lung cancerâ€”an academic dilemma. <b>2016</b> , 9, 109-110	1
2089	Immune Checkpoint Inhibitor Therapy as a Novel and Effective Therapy for Aggressive Cutaneous Squamous-cell Carcinoma. <b>2016</b> , 1, 75-81	7
2088	Immune Therapy for Prostate Cancer. <b>2016</b> , 22, 334-341	10
2087	Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors. <b>2016</b> , 39, 367-372	61
2086	Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials. <b>2016</b> , 95, e4611	36

2085	Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. <b>2016</b> , 4, 84	72
2084	Oncologie thoracique. <b>2016</b> , 8, 268-272	
2083	Traitement de seconde ligne et au-delà des cancers bronchopulmonaires non à petites cellules de stade IV en l'absence d'addiction oncogène. <b>2016</b> , 8, 361-372	
2082	Prise en charge des métastases cérébrales des carcinomes bronchiques. <b>2016</b> , 8, 425-433	
2081	Toxicité hématologiques et digestives en cancérologie thoracique. <b>2016</b> , 8, 478-488	
2080	Les cancers bronchiques non à petites cellules EGFR-mutés. <b>2016</b> , 8, 373-381	
2079	CBNPC avec translocation ALK/ROS. <b>2016</b> , 8, 382-386	
2078	Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. <b>2016</b> , 107, 1730-1735	75
2077	Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases. <b>2016</b> , 4, 80	64
2076	Learning from the "tsunami" of immune checkpoint inhibitors in 2015. <b>2016</b> , 101, 213-20	30
2075	Monitoring immune responses in the tumor microenvironment. <b>2016</b> , 41, 23-31	76
2074	Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma. <b>2016</b> , 46, 63-72	10
2073	Can immunostimulatory agents enhance the abscopal effect of radiotherapy?. <b>2016</b> , 62, 36-45	81
2072	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. <b>2016</b> , 9, 47	221
2071	Are there, or shall we discover, biomarkers to guide PD-1 inhibition?. <b>2016</b> , 8, 681-6	1
2070	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. <b>2016</b> , 76, 925-45	100
2069	EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. <b>2016</b> , 22, 4585-93	655
2068	Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. <b>2016</b> , 27, 1706-12	71

2067	Beyond monotherapy: Integrating immunotherapy into current treatment regimens. <b>2016</b> , 11, S8-S9	
2066	PD-L1 Expression in Lung Cancer. <b>2016</b> , 11, 964-75	201
2065	Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer. <b>2016</b> , 76, 969-78	19
2064	Targeting T Cell Co-receptors for Cancer Therapy. <b>2016</b> , 44, 1069-78	314
2063	Targeting PD-L1 for non-small-cell lung cancer. <b>2016</b> , 8, 747-58	10
2062	Silymarin suppressed lung cancer growth in mice via inhibiting myeloid-derived suppressor cells. <b>2016</b> , 81, 460-467	13
2061	Targeting K-Ras cancers. <b>2016</b> , 11, S9-S10	
2060	PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. <b>2016</b> , 29, 1104-12	153
2059	Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. <b>2016</b> , 76, 3767-72	98
2058	The fourth modality: immunotherapy for head and neck cancer hits pay dirt. <b>2016</b> , 121, 575-7	3
2057	Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. <b>2016</b> , 352, 189-96	1961
2056	Into the Clinic With Nivolumab and Pembrolizumab. <b>2016</b> , 21, 527-8	10
2055	Immune checkpoint inhibitors: a patent review (2010-2015). <b>2016</b> , 26, 555-64	41
2054	Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases. <b>2016</b> , 27, 1354-6	33
2053	What are the options for hepatocellular carcinoma patients who progress under sorafenib?. <b>2016</b> , 3, 105-108	1
2052	Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer. <b>2016</b> , 77, 1031-8	9
2051	Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. <b>2016</b> , 27, 1482-92	335
2050	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. <b>2016</b> , 16, 275-87	1444

2049	Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. <b>2016</b> , 16, 989-1004	9
2048	The role of neoantigens in response to immune checkpoint blockade. <b>2016</b> , 28, 411-9	88
2047	MicroRNAs provide a novel pathway toward combinatorial immune checkpoint blockade. <b>2016</b> , 18, 601-2	1
2046	The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. <b>2016</b> , 22, 1865-74	421
2045	Emerging Opportunities and Challenges in Cancer Immunotherapy. <b>2016</b> , 22, 1845-55	172
2044	Advances in immunotherapy for melanoma. <b>2016</b> , 14, 20	79
2043	Thymic malignancies: Moving forward with new systemic treatments. <b>2016</b> , 46, 27-34	4
2042	Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. <b>2016</b> , 27, 1286-91	64
2041	Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. <b>2016</b> , 9, 34	189
2040	Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?. <b>2016</b> , 17, 350-361	83
2039	FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. <b>2016</b> , 21, 634-42	274
2038	Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer. <b>2016</b> , 17, 25	13
2037	Immune checkpoint inhibition in ovarian cancer. <b>2016</b> , 28, 339-48	96
2036	Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. <b>2016</b> , 140, 341-4	98
2035	The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival. <b>2016</b> , 114, 1145-51	22
2034	Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. <b>2016</b> , 24, 3633-50	23
2033	Mass spectrometry-based antigen discovery for cancer immunotherapy. <b>2016</b> , 41, 9-17	92
2032	BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?. <b>2016</b> , 101, 32-9	13

2031	High co-expression of PD-L1 and HIF-1 $\beta$ correlates with tumour necrosis in pulmonary pleomorphic carcinoma. <b>2016</b> , 60, 125-35	71
2030	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. <b>2016</b> , 12, 2219-31	33
2029	A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. <b>2016</b> , 8, 665-74	30
2028	Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. <b>2016</b> , 8, 583-600	52
2027	Recent developments in the use of immunotherapy in non-small cell lung cancer. <b>2016</b> , 10, 781-98	23
2026	Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. <b>2016</b> , 28, 373-82	108
2025	What's hot in lung cancer. <b>2016</b> , 37, 79-85	
2024	Medikamentöse Behandlung des Lungenkarzinoms – Grundlagen und neue Säulen der Therapie. <b>2016</b> , 45, 140-147	
2023	Roles of regulatory T cells in cancer immunity. <b>2016</b> , 28, 401-9	280
2022	Current Challenges in Cancer Treatment. <b>2016</b> , 38, 1551-66	318
2021	Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer. <b>2016</b> , 28, 122-9	37
2020	Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor-Directed Therapies Fail. <b>2016</b> , 12, 412-20	10
2019	TG4010: a vaccine with a therapeutic role in cancer. <b>2016</b> , 8, 511-9	11
2018	PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. <b>2016</b> , 5, e1131379	73
2017	Perspectives for immunotherapy in endocrine cancer. <b>2016</b> , 23, R469-84	10
2016	Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab. <b>2016</b> , 8, 1163-7	9
2015	PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. <b>2016</b> , 4, 48	145
2014	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer. <b>2016</b> , 64, 587-600	24

2013	Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. <b>2016</b> , 100, 77-84	70
2012	Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma. <b>2016</b> , 46, 935-941	45
2011	Challenge of Prognostic Uncertainty in the Modern Era of Cancer Therapeutics. <b>2016</b> , 34, 3605-3608	52
2010	Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation. <b>2016</b> , 130, 397-411	10
2009	[Therapy of Metastatic Non-small Cell Lung Cancer]. <b>2016</b> , 70, 567-78	1
2008	A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy. <b>2016</b> , 115, 784-8	10
2007	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. <b>2016</b> , 17, 1590-1598	450
2006	[Not Available]. <b>2016</b> , 103, S12-5	0
2005	The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update. <b>2016</b> , 10, 1229-1241	9
2004	Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies. <b>2016</b> , 7, e2380	25
2003	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. <b>2016</b> , 17, 2253-2266	22
2002	The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer. <b>2016</b> , 16, 1119-1129	1
2001	Trends and advances in tumor immunology and lung cancer immunotherapy. <b>2016</b> , 35, 157	34
2000	[Immunotherapy for HNSCC : Quo vadis?]. <b>2016</b> , 64, 700-7	0
1999	Cancers bronchiques : des nouveautés à affiner pour la routine. <b>2016</b> , 18, 363-364	
1998	Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer. <b>2016</b> , 115, 549-52	10
1997	The genomic landscape of breast cancer and its interaction with host immunity. <b>2016</b> , 29, 241-50	130
1996	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. <b>2016</b> , 17, 1497-1508	954

1995	Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines. <b>2016</b> , 40, 151-162		16
1994	Immunotherapy for rectal carcinoma: Some stimulating data but still a long way to clinical evidence. <b>2016</b> , 68, 70-72		
1993	Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. <b>2016</b> , 16, 744		81
1992	WITHDRAWN: Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. <b>2016</b> , 243, 21-28		3
1991	Immunotherapy for Lung Cancer: No Longer an Abstract Concept. <b>2016</b> , 37, 771-782		8
1990	Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer. <b>2016</b> , 37, 760-770		33
1989	Genomic Approaches to Understanding Response and Resistance to Immunotherapy. <b>2016</b> , 22, 5642-5650		98
1988	Immune checkpoint inhibitors: a new class of anticancer drug. <b>2016</b> , 27, 23-28		1
1987	Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. <b>2016</b> , 113, 11919-11924		127
1986	Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future?. <b>2016</b> , 28, 726-731		6
1985	Divide and Conquer to Treat Lung Cancer. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1892-1893	59.2	12
1984	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1856-1867	59.2	2647
1983	Optimum treatment for mediastinal lymph node positive (N2) resectable non-small cell lung cancer: what is the role for surgery?. <b>2016</b> , 16, 1131-1144		
1982	Genomic insights into head and neck cancer. <b>2016</b> , 1,		51
1981	Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. <b>2016</b> , 6, 1382-1399		356
1980	Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma. <b>2016</b> , 99, 166-71		36
1979	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. <b>2016</b> , 34, 3638-3647		108
1978	Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. <b>2016</b> , 99, 79-87		85



1977	Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A Review. <b>2016</b> , 2, 1490-1495	53
1976	The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer. <b>2016</b> , 16, 903-10	5
1975	Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence. <b>2016</b> , 10, 444-54	18
1974	Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. <b>2016</b> , 18, 59	28
1973	PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. <b>2016</b> , 8, 1081-9	24
1972	Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. <b>2016</b> , 34, 677-684	22
1971	The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. <b>2016</b> , 63, 1490-1493	156
1970	The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. <b>2016</b> , 21, 910-21	42
1969	[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study]. <b>2016</b> , 37, 557-567	31
1968	Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies. <b>2016</b> , 11, 1927-1939	42
1967	Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. <b>2016</b> , 5, 2567-78	45
1966	PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?. <b>2016</b> , 22, 4539-41	31
1965	Management of Stage IIIA (N2) Non-Small Cell Lung Cancer. <b>2016</b> , 26, 271-85	13
1964	Chemotherapy remains an essential element of personalized care for persons with lung cancers. <b>2016</b> , 27, 1829-35	52
1963	Pembrolizumab in classical Hodgkin's lymphoma. <b>2016</b> , 97, 219-27	16
1962	The immune system and cancer evasion strategies: therapeutic concepts. <b>2016</b> , 279, 541-62	146
1961	Immunotherapy for lung cancer. <b>2016</b> , 21, 821-33	126
1960	The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope. <b>2016</b> , 12, 2713-2727	16

1959	PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. <b>2016</b> , 36, 317-34	57
1958	Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC. <b>2016</b> , 11, 1954-1961	8
1957	EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. <b>2016</b> , 9, 59	113
1956	Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy. <b>2016</b> , 34, 794-796	14
1955	Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. <b>2016</b> , 11, 1869-1878	66
1954	Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. <b>2016</b> , 27, 2004-2016	71
1953	Lymphocyte-activation gene-3, an important immune checkpoint in cancer. <b>2016</b> , 107, 1193-7	115
1952	Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301. <b>2016</b> , 99, 41-5	24
1951	Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy. <b>2016</b> , 27, 1966-9	19
1950	Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse. <b>2016</b> , 46, 1392-1398	4
1949	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. <b>2016</b> , 388, 1002-11	113
1948	New and emerging targeted treatments in advanced non-small-cell lung cancer. <b>2016</b> , 388, 1012-24	299
1947	Management of Lung Cancer in the Elderly. <b>2016</b> , 170, 251-84	8
1946	An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers. <b>2016</b> , 12, 1255-61	9
1945	Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harboring Targetable Oncogenic Driver Mutations. <b>2016</b> , 76, 1321-36	14
1944	Clinician Perspectives on Current Issues in Lung Cancer Drug Development. <b>2016</b> , 11, 1387-96	6
1943	Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. <b>2016</b> , 76, 5994-6005	136
1942	Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogenic primary and metastatic lung cancer: Implications for immunotherapy. <b>2016</b> , 5, e1213934	53

1941	Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis. <b>2016</b> , 11, 2238-2240	101
1940	Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. <b>2016</b> , 27, 1953-8	195
1939	Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer. <b>2016</b> , 27, 2117-2123	92
1938	Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. <b>2016</b> , 100, 38-44	4
1937	PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. <b>2016</b> , 22, 6051-6060	292
1936	Diagnosis and Molecular Classification of Lung Cancer. <b>2016</b> , 170, 25-46	84
1935	Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression. <b>2016</b> , 5, 119-122	5
1934	Emerging role of immunotherapy in urothelial carcinoma-Advanced disease. <b>2016</b> , 34, 538-547	28
1933	Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. <b>2016</b> , 4, 72	104
1932	Lung cancer in 2016: immunotherapy comes of age. <b>2016</b> , 4, 947-949	9
1931	Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations. <b>2016</b> , 4, 77	68
1930	Robust Ki67 detection in human blood by flow cytometry for clinical studies. <b>2016</b> , 8, 2399-2413	8
1929	Understanding immunotherapy for the treatment of non-small cell lung cancer. <b>2016</b> , 25, S12-7	1
1928	PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher. <b>2016</b> , 9, 939-49	9
1927	Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. <b>2016</b> , 5, e1214788	97
1926	Update in Lung Cancer 2015. <b>2016</b> , 194, 661-71	10
1925	Immunotherapy for prostate cancer: False promises or true hope?. <b>2016</b> , 122, 3598-3607	19
1924	Current management and future directions in metastatic pancreatic adenocarcinoma. <b>2016</b> , 122, 3765-3775	14

1923	Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. <b>2016</b> , 5, e1231292	70
1922	Loss of IFN- $\gamma$ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. <b>2016</b> , 167, 397-404.e9	688
1921	Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy. <b>2016</b> , 61, 166-76	9
1920	Checkpoint inhibitors in lung cancer: latest developments and clinical potential. <b>2016</b> , 8, 460-473	26
1919	Lung cancer: First-line immunotherapy in lung cancer - taking the first step. <b>2016</b> , 13, 595-6	3
1918	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. <b>2016</b> , 34, 3740-3748	319
1917	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <b>2016</b> , 17, 1283-94	643
1916	Novel therapeutic targets on the horizon for lung cancer. <b>2016</b> , 17, e347-e362	120
1915	PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. <b>2016</b> , 58, 7-14	99
1914	Treatment of Stage IIIA Non-Small-Cell Lung Cancer: A Concise Review for the Practicing Oncologist. <b>2016</b> , 12, 601-6	10
1913	Group sequential monitoring based on the weighted log-rank test statistic with the Fleming-Harrington class of weights in cancer vaccine studies. <b>2016</b> , 15, 412-9	15
1912	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). <b>2016</b> , 130, 19-29	71
1911	Immunotherapy for head and neck squamous cell carcinoma. <b>2016</b> , 9, 66-69	20
1910	Management of non-small cell lung cancer in the era of personalized medicine. <b>2016</b> , 78, 173-179	18
1909	Drug discovery in advanced prostate cancer: translating biology into therapy. <b>2016</b> , 15, 699-718	77
1908	Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. <b>2016</b> , 22, 4550-5	55
1907	Immuntherapie des Lungenkarzinoms. <b>2016</b> , 13, 249-254	
1906	Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. <b>2016</b> , 99, 162-5	31

1905	Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report. <b>2016</b> , 99, 148-50	41
1904	SCLC-State of the Art and What Does the Future Have in Store?. <b>2016</b> , 17, 325-333	34
1903	Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. <b>2016</b> , 30, 397-405	31
1902	Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma. <b>2016</b> , 9, 184-90	26
1901	Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <b>2016</b> , 34, 3204-12	35
1900	Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. <b>2016</b> , 16, 1209-23	14
1899	Optimal design and endpoint of clinical trials using immune checkpoint blocking agents. <b>2016</b> , 16, 1217-1218	2
1898	Therapy for EGFR tyrosine kinase inhibitor-resistant NSCLC with a focus on the T790M-resistant mutation. <b>2016</b> , 9, 187-190	
1897	Ramucirumab for the treatment of advanced or metastatic non-small cell lung cancer. <b>2016</b> , 16, 1541-1547	2
1896	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <b>2016</b> , 30, 571-584	66
1895	Immunothérapie et cancer du sein. <b>2016</b> , 18, 551-558	2
1894	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. <b>2016</b> , 1, e000066	14
1893	Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options. <b>2016</b> , 1, e000081	5
1892	Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. <b>2016</b> , 4, 1038-1048	54
1891	FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer. <b>2016</b> , 14, 238	22
1890	Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. <b>2016</b> , 113, E7759-E7768	234
1889	Combination approaches in NSCLC involving immune checkpoint inhibitors. <b>2016</b> , 5, 163-171	1
1888	Making urothelial carcinomas less immune to immunotherapy. <b>2016</b> , 34, 534-537	1

1887	Targeting the PD-1/PD-L1 axis in the treatment of lung cancer. <b>2016</b> , 7, 17-27	
1886	Checkpoint Inhibitors in Lung Cancer Are Not Immune from Cost-Effectiveness Analysis. <b>2016</b> , 11, 1814-1816	11
1885	Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. <b>2016</b> , 4, 68	20
1884	Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. <b>2016</b> , 4, 60	46
1883	Facteurs prédictifs et biomarqueurs précoces de réponse aux inhibiteurs de checkpoint immunologiques (anti-PD-1, anti-PD-L1). <b>2016</b> , 18, 533-542	2
1882	Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. <b>2016</b> , 17, 1661-1671	86
1881	Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. <b>2016</b> , 17, 1653-1660	277
1880	Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. <b>2016</b> , 43, 638-646	38
1879	Diminished but not dead: chemotherapy for the treatment of NSCLC. <b>2016</b> , 17, 1464-1465	14
1878	The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis. <b>2016</b> , 6, 32020	14
1877	Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression. <b>2016</b> , 102, 44-48	55
1876	Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. <b>2016</b> , 21, 1450-1460	70
1875	PD-L1 testing, fit for routine evaluation? From a pathologist's point of view. <b>2016</b> , 9, 201-206	28
1874	Drug selection for anaplastic lymphoma kinase-positive non-small-cell lung cancer. <b>2016</b> , 17, 1627-1628	
1873	Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. <b>2016</b> , 102, 89-95	137
1872	Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment. <b>2016</b> , 6, 31745	18
1871	From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?. <b>2016</b> , 17, 59	3
1870	Role of multimodality therapy in cIIIA-N2 non-small cell lung cancer: perspective. <b>2016</b> , 46, 1174-1178	3

1869	Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. <b>2016</b> , 10, 383-388	62
1868	Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. <b>2016</b> , 27, 2242-2250	65
1867	Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial. <b>2016</b> , 68, 156-162	88
1866	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. <b>2016</b> , 102, 21-27	10
1865	Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. <b>2016</b> , 102, 65-73	61
1864	Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. <b>2016</b> , 17, 1213-1220	38
1863	Lung Cancer Subtypes Generate Unique Immune Responses. <b>2016</b> , 197, 4493-4503	81
1862	Current status of immunotherapy for non-small-cell lung cancer. <b>2016</b> , 102, 337-51	6
1861	Imaging Biomarkers in Immunotherapy. <b>2016</b> , 8, 1-13	24
1860	Highlights for ESMO 40: celebration review for lifetime achievement awards. <b>2016</b> , 1, e000010	
1859	Review of the British Thoracic Society Winter Meeting 2015, 2-4 December, London, UK. <b>2016</b> , 71, 555-9	
1858	Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet. <b>2016</b> , 2016, 223-5	5
1857	Programmed Death-1 Inhibition in Cancer With a Focus on Non-Small Cell Lung Cancer: Rationale, Nursing Implications, and Patient Management Strategies. <b>2016</b> , 20, 319-26	3
1856	Immunotherapy for Lung Cancer: Many Questions Yet to Be Answered. <b>2016</b> , 14, 935-8	1
1855	Zielgerichtete und immunologische Therapie beim NSCLC. <b>2016</b> , 19, 56-62	
1854	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2016</b> , 27, v1-v27	590
1853	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" Napoli, December 5th 2015. <b>2016</b> , 4,	78
1852	It's TIME for a biomarker-driven approach to cancer immunotherapy. <b>2016</b> , 4, 43	5

1851	Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective. <b>2016</b> , 31, 238-42	1
1850	Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. <b>2016</b> , 4, 34	18
1849	Quality of life of cancer patients on the wave of immunotherapy. <b>2016</b> , 1, 351-352	
1848	Best Practices in Treatment Selection for Patients With Advanced NSCLC. <b>2016</b> , 23, 2-14	5
1847	Immunotherapy of Colorectal Cancer. <b>2016</b> , 39, 346-50	7
1846	Progress in Cancer Immunotherapy. <b>2016</b> ,	5
1845	Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. <b>2016</b> , 43, 1954-61	87
1844	Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. <b>2016</b> , 142, 1727-38	56
1843	Congress Report ESMO Asia 2015. <b>2016</b> , 9, 35-50	
1842	Blockade von Immuncheckpoints. <b>2016</b> , 31, 226-229	
1841	Harnessing the antitumor immunity cycle to treat lung cancer. <b>2016</b> , 5, 40-48	
1840	Impact of genomic sequencing on precision medicine for clinical oncology. <b>2016</b> , 1, 255-265	
1839	Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. <b>2016</b> , 17, 984-993	498
1838	Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer. <b>2016</b> , 17, e179-e183	4
1837	Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France. <b>2016</b> , 8, 999-1009	26
1836	Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). <b>2016</b> , 98, 69-75	114
1835	Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. <b>2016</b> , 48, 20-4	90
1834	Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. <b>2016</b> , 29, 1028-37	62



1833	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. <b>2016</b> , 4, 679-87	54
1832	Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. <b>2016</b> , 34, 3119-25	601
1831	A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing. <b>2016</b> , 11, 1846-1855	67
1830	Recent results of immunotherapy and perspectives for advanced NSCLC. <b>2016</b> , 5, 57-60	
1829	Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. <b>2016</b> , 11, 1819-1836	22
1828	Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma. <b>2016</b> , 11, 1879-1890	118
1827	Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. <b>2016</b> , 43, 501-13	8
1826	Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. <b>2016</b> , 12, 1805-22	6
1825	Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. <b>2016</b> , 97, 73-80	96
1824	Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. <b>2016</b> , 98, 76-78	24
1823	Brèves de l'AJRO. <b>2016</b> , 18, 194-197	
1822	Nivolumab beim NSCLC – erste Phase-III-Daten. <b>2016</b> , 19, 25-26	
1821	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. <b>2016</b> , 17, 976-983	666
1820	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. <b>2016</b> , 17, 883-895	783
1819	Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer. <b>2016</b> , 6, 20-23	19
1818	Head and neck cancer immunology and immunotherapeutics: Basic concepts to clinical translational approaches. <b>2016</b> , 58, 49-51	
1817	Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer. <b>2016</b> , 22, 3713-7	49
1816	Genomic determinants of cancer immunotherapy. <b>2016</b> , 41, 32-38	20

1815	Genetic profiling of hepatocellular carcinoma using next-generation sequencing. <b>2016</b> , 65, 1031-1042	156
1814	Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not. <b>2016</b> , 97, 15-21	32
1813	Nintedanib in NSCLC: evidence to date and place in therapy. <b>2016</b> , 8, 188-97	17
1812	Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy. <b>2016</b> , 57, 1607-1611	84
1811	Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung. <b>2016</b> , 17, 391-397	43
1810	The Utility of Exercise Testing in Patients with Lung Cancer. <b>2016</b> , 11, 1397-410	35
1809	Successes and Failures of Combined Modality Therapies in Head and Neck Cancer. <b>2016</b> , 26, 299-306	3
1808	The use of biomarkers in the treatment of non-small cell lung cancer. <b>2016</b> , 1, 25-36	2
1807	The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology. <b>2016</b> , 12, 339-83	93
1806	Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. <b>2016</b> , 2, 1217-22	165
1805	Immune Checkpoint Inhibitors in Older Adults. <b>2016</b> , 18, 47	40
1804	Practice pearls in the management of lung cancer in the elderly. <b>2016</b> , 7, 362-7	5
1803	Stratification in advanced non-small cell lung cancer: precision medicine in practice. <b>2016</b> , 1, 279-287	1
1802	Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. <b>2016</b> , 11, 1511-21	74
1801	[Cancer immunotherapy: Rational and recent breakthroughs]. <b>2016</b> , 37, 694-700	22
1800	Ovarian cancer patients' and their family members' perspectives on novel vaccine and virotherapy trials. <b>2016</b> , 13, 660-664	1
1799	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. <b>2016</b> , 4, 3	146
1798	Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors?. <b>2016</b> , 12, 429-31	2

1797	The calm before the storm: a report from the International Liver Cancer Association Congress 2015 - part 2. <b>2016</b> , 12, 285-8	1
1796	Doubling the blockade for melanoma immunotherapy. <b>2016</b> , 5, e1106127	9
1795	Novel challenges associated with novel agents: the evolving scenario in renal cell carcinoma. <b>2016</b> , 12, 277-9	
1794	Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent. <b>2016</b> , 33, 13	10
1793	Pembrolizumab for the treatment of non-small cell lung cancer. <b>2016</b> , 16, 397-406	52
1792	T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients. <b>2016</b> , 22, 3057-66	154
1791	Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. <b>2016</b> , 48, 177-87	141
1790	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <b>2016</b> , 387, 1540-1550	3964
1789	Best Lung Cancer Research, 2015. <b>2016</b> , 38, 1	
1788	CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. <b>2016</b> , 39, 98-106	1102
1787	How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. <b>2016</b> , 21, 233-43	45
1786	PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non-Small-Cell Lung Cancer. <b>2016</b> , 2, 569-570	5
1785	The Value of PD-L1 Testing in Non-Small-Cell Lung Cancer. <b>2016</b> , 2, 571-572	14
1784	A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study. <b>2016</b> , 17, 232-236.e1	103
1783	2015 and human cancer: back to overall survival. <b>2016</b> , 12, 1751-4	
1782	Scientific Advances in Lung Cancer 2015. <b>2016</b> , 11, 613-638	164
1781	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. <b>2016</b> , 130, 25-74	119
1780	Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient. <b>2016</b> , 34, 1438-42	15

1779	PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. <b>2016</b> , 93, 9-16	23
1778	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. <b>2016</b> , 93, 59-68	87
1777	Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. <b>2016</b> , 12, 1045-58	7
1776	Immune checkpoint therapy for non-small-cell lung cancer: an update. <b>2016</b> , 8, 279-98	50
1775	PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?. <b>2016</b> , 140, 351-4	11
1774	Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine. <b>2016</b> , 382, 118-126	11
1773	[Asbestos and respiratory diseases]. <b>2016</b> , 45, 117-32	2
1772	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. <b>2016</b> , 11, 469-77	31
1771	Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer. <b>2016</b> , 17, 169-76	15
1770	The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. <b>2016</b> , 17, 161-8	13
1769	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. <b>2016</b> , 45, 7-18	264
1768	Management of toxicities of immune checkpoint inhibitors. <b>2016</b> , 44, 51-60	522
1767	Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 493-4	59.2 37
1766	[PD-L1 expression: An emerging biomarker in non-small cell lung cancer]. <b>2016</b> , 36, 94-102	5
1765	[2015 through the eyes of the Bulletin of Cancer editorial board]. <b>2016</b> , 103, 3-17	1
1764	Immunotherapy for pancreatic cancer. <b>2016</b> , 142, 1795-805	22
1763	Immunotherapy and Oncogenic Pathways: The PTEN Connection. <b>2016</b> , 6, 128-9	16
1762	The race for combined checkpoint inhibition in NSCLC. <b>2016</b> , 17, 259-260	3

1761	Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?. <b>2016</b> , 140, 326-31	99
1760	TIME for a successful cancer vaccine in NSCLC?. <b>2016</b> , 17, 131-132	1
1759	The management of immune-related adverse events associated with immune checkpoint blockade. <b>2016</b> , 1, 89-97	11
1758	Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice. <b>2016</b> , 35, 141-50	22
1757	The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer. <b>2016</b> , 17, 18	14
1756	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. <b>2016</b> , 21, 462-73	190
1755	Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. <b>2016</b> , 57, 91-103	95
1754	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. <b>2016</b> , 468, 511-25	172
1753	Tubulin inhibitors in non-small cell lung cancer: looking back and forward. <b>2016</b> , 17, 1113-29	18
1752	Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. <b>2016</b> , 101, 75-85	84
1751	Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future. <b>2016</b> , 37, 7021-31	93
1750	Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. <b>2016</b> , 18, 1137-45	88
1749	Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma. <b>2016</b> , 387, 1881-2	4
1748	MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. <b>2016</b> , 44, 609-621	412
1747	A catalogue of treatment and technologies for malignant pleural mesothelioma. <b>2016</b> , 16, 455-63	11
1746	Targeted agents and combinations in ovarian cancer: where are we now?. <b>2016</b> , 16, 441-54	10
1745	Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer. <b>2016</b> , 11, 976-88	161
1744	Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. <b>2016</b> , 4, 289-93	112

1743	Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCEVIH Working Group. <b>2016</b> , 27, 397-408	31
1742	Emerging immunotherapy for the treatment of esophageal cancer. <b>2016</b> , 25, 667-77	21
1741	Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <b>2016</b> , 387, 1837-46	1731
1740	PD-L1 in non-small-cell lung cancer: the third target for immunotherapy. <b>2016</b> , 387, 1795-6	9
1739	Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. <b>2016</b> , 15, 235-47	358
1738	Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <b>2016</b> , 10, 183-93	90
1737	Recent advances in the management of pulmonary sarcomatoid carcinoma. <b>2016</b> , 10, 407-416	13
1736	Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. <b>2016</b> , 45, 30-7	168
1735	OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment. <b>2016</b> , 52, 1-10	41
1734	Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets. <b>2016</b> , 13, 75-6	8
1733	Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?. <b>2016</b> , 387, 1488-14908	
1732	TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value. <b>2016</b> , 99, 63-73	52
1731	Mutanome directed cancer immunotherapy. <b>2016</b> , 39, 14-22	44
1730	Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. <b>2016</b> , 16, 131-3	46
1729	Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. <b>2017</b> , 17, 528-534	7
1728	Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). <b>2017</b> , 19, 31-43	17
1727	Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician. <b>2017</b> , 29, 245-251	19
1726	Successful Treatment of an Aggressive Tracheal Malignancy With Immunotherapy. <b>2017</b> , 103, e123-e125	4

1725	High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. <b>2017</b> , 104, 1-6	110
1724	Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer. <b>2017</b> , 104, 111-118	64
1723	Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. <b>2017</b> , 30, 530-538	68
1722	Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. <b>2017</b> , 33, 749-759	50
1721	Immunomodulatory Activity of VEGF in Cancer. <b>2017</b> , 330, 295-342	95
1720	[Perioperative therapies in surgical non N2 non-small cell lung cancer]. <b>2017</b> , 104, 79-85	1
1719	High Frequency of Programmed Death-ligand 1 Expression in Emphysematous Bullae-associated Lung Adenocarcinomas. <b>2017</b> , 18, 504-511.e1	10
1718	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. <b>2017</b> , 110, 106-116	29
1717	Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. <b>2017</b> , 53, 128-137	91
1716	Renal complications of immune checkpoint blockade. <b>2017</b> , 41, 100-110	61
1715	Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. <b>2017</b> , 3, 502-509	18
1714	EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer. <b>2017</b> , 18, 527-534.e1	86
1713	Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity?. <b>2017</b> , 29, 207-217	5
1712	Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. <b>2017</b> , 73, 1-8	279
1711	PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?. <b>2017</b> , 17, 305-312	34
1710	Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. <b>2017</b> , 53, 111-119	97
1709	Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. <b>2017</b> , 106, 1-7	294
1708	Beyond platinum treatment for NSCLC: what does the future hold?. <b>2017</b> , 17, 293-295	7

1707	Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch. <b>2017</b> , 10, 84-92	72
1706	Pharmacological management of relapsed/refractory NSCLC with chemical drugs. <b>2017</b> , 18, 295-304	10
1705	Checkpoint inhibition: new treatment options in urologic cancer. <b>2017</b> , 72, 24-28	8
1704	Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis. <b>2017</b> , 54, 34-42	39
1703	Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. <b>2017</b> , 174, 1-21	87
1702	Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy. <b>2017</b> , 35, 217-226	11
1701	T cell exhaustion: from pathophysiological basics to tumor immunotherapy. <b>2017</b> , 15, 1	116
1700	Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program. <b>2017</b> , 19, 761-768	8
1699	Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer. <b>2017</b> , 23, 3585-3591	215
1698	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. <b>2017</b> , 5, 106-117	162
1697	Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy. <b>2017</b> , 4, e000163	6
1696	An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer. <b>2017</b> , 12, 791-803	85
1695	Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer. <b>2017</b> , 105, 17-22	36
1694	Radiotherapy and immunotherapy: a beneficial liaison?. <b>2017</b> , 14, 365-379	504
1693	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. <b>2017</b> , 18, 312-322	981
1692	Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials. <b>2017</b> , 18, 345-353.e5	14
1691	Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. <b>2017</b> , 31, 2181-2190	132
1690	LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. <b>2017</b> , 23, 3316-3324	28



1689	Targeting ALK: Precision Medicine Takes on Drug Resistance. <b>2017</b> , 7, 137-155	269
1688	A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1). <b>2017</b> , 17, 199-201	9
1687	Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review. <b>2017</b> , 18, 444-459.e1	56
1686	Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. <b>2017</b> , 75, 24-32	118
1685	Cardiovascular Toxicities Associated with Cancer Immunotherapies. <b>2017</b> , 19, 21	99
1684	[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment]. <b>2017</b> , 37, 46-54	1
1683	Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. <b>2017</b> , 75, 141-149	66
1682	Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. <b>2017</b> , 17, 387-394	89
1681	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. <b>2017</b> , 6, e1286437	21
1680	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. <b>2017</b> , 23, 4270-4279	84
1679	Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition. <b>2017</b> , 203, 128-138	16
1678	Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. <b>2017</b> , 25, 1713-1739	82
1677	Targeting neoantigens to augment antitumour immunity. <b>2017</b> , 17, 209-222	449
1676	[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers]. <b>2017</b> , 37, 61-78	10
1675	PD-1 and PD-L1 antibodies in cancer: current status and future directions. <b>2017</b> , 66, 551-564	188
1674	Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. <b>2017</b> , 38, 513-525	25
1673	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1015-1026	59.2 1788
1672	Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. <b>2017</b> , 143, 783-791	22

1671	Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer. <b>2017</b> , 67, 52-60	37
1670	MEDI1873, a potent, stabilized hexameric agonist of human GTR with regulatory T-cell targeting potential. <b>2017</b> , 6, e1280645	15
1669	Response Evaluation in Head and Neck Oncology: Definition and Prediction. <b>2017</b> , 79, 14-23	5
1668	PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. <b>2017</b> , 7, 44173	50
1667	Standard of care in immunotherapy trials: Challenges and considerations. <b>2017</b> , 13, 2164-2178	4
1666	Assays for PD-L1 Expression: Do All Roads Lead to Rome?. <b>2017</b> , 3, 1058-1059	4
1665	A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. <b>2017</b> , 3, 1051-1058	491
1664	The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. <b>2017</b> , 8, 14638	38
1663	EGFR TKI combination with immunotherapy in non-small cell lung cancer. <b>2017</b> , 16, 465-469	104
1662	Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. <b>2017</b> , 22, 470-479	166
1661	The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly. <b>2017</b> , 17, 565-571	22
1660	The safety of second-line treatment options for non-small cell lung cancer. <b>2017</b> , 16, 471-479	2
1659	Large Cell Neuroendocrine Carcinoma. <b>2017</b> , 293-304	1
1658	Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients. <b>2017</b> , 139, 30-36	27
1657	Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis. <b>2017</b> , 9, 261-272	24
1656	Looking back and to the future: 'Are we improving 'cure' in non-small cell lung cancer?. <b>2017</b> , 75, 192-194	10
1655	Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer. <b>2017</b> , 92, 283-290	31
1654	Biomarkers and the 'target therapies' in oncology, research and business. <b>2017</b> , 11, 217-219	1

- 1653 Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. **2017**, 5, 312-318 259
- 1652 Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis. **2017**, 43, 1372-1379 22
- 1651 iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. **2017**, 18, e143-e152 1010
- 1650 China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version). **2017**, 13, 87-103 29
- 1649 Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches. **2017**, 106, 70-75 26
- 1648 Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation. **2017**, 15, 5 23
- 1647 LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. **2017**, 12, 814-823 122
- 1646 DNA vaccines for prostate cancer. **2017**, 174, 27-42 25
- 1645 Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. **2017**, 45, 160-169 220
- 1644 Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis. **2017**, 101, 657-666 89
- 1643 Strategies for Translating Evidence-Based Medicine in Lung Cancer into Community Practice. **2017**, 19, 5
- 1642 Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence. **2017**, 34, 34 20
- 1641 Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. **2017**, 10, 64 20
- 1640 Checkpoint Blockade in Lung Cancer and Mesothelioma. **2017**, 196, 274-282 42
- 1639 Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities. **2017**, 153, 285-290 24
- 1638 The CD47-SIRP $\alpha$  signaling axis as an innate immune checkpoint in cancer. **2017**, 276, 145-164 225
- 1637 Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. **2017**, 5, 319-329 9
- 1636 Biological therapies in nonsmall cell lung cancer. **2017**, 49, 29

1635	Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. <b>2017</b> , 13, 1159-1171	12
1634	Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma. <b>2017</b> , 6, e1269047	35
1633	Stage IV advanced diffuse large B-cell lymphoma in human immunodeficiency virus infection with achieving cure by using highly active antiretroviral therapy alone: a case report. <b>2017</b> , 28, 932-936	4
1632	Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data. <b>2017</b> , 141, 1018-1028	79
1631	A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. <b>2017</b> , 18, 572-582.e1	39
1630	Extracellular vesicles in lung cancer-From bench to bedside. <b>2017</b> , 67, 39-47	38
1629	Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. <b>2017</b> , 12, 153-161	20
1628	Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study. <b>2017</b> , 13, 137-144	2
1627	Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials. <b>2017</b> , 44, 3-7	63
1626	Bladder cancer immunotherapy: swinging for the fences. <b>2017</b> , 13, 773-775	
1625	Radiotherapy in the age of cancer immunology: Current concepts and future developments. <b>2017</b> , 112, 1-10	16
1624	Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab. <b>2017</b> , 8, 175-180	4
1623	Ramucirumab in the treatment of non-small cell lung cancer. <b>2017</b> , 16, 637-644	17
1622	Increased Soluble CD226 in Sera of Patients with Cutaneous T-Cell Lymphoma Mediates Cytotoxic Activity against Tumor Cells via CD155. <b>2017</b> , 137, 1766-1773	13
1621	Pembrolizumab in recurrent advanced cervical squamous carcinoma. <b>2017</b> , 9, 467-470	10
1620	irRECIST and iRECIST: the devil is in the details. <b>2017</b> , 28, 1676-1678	21
1619	Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy. <b>2017</b> , 62, 205-213	8
1618	Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. <b>2017</b> , 78, 16-23	75

1617	Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature. <b>2017</b> , 108, 217-221	25
1616	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <b>2017</b> , 389, 2492-2502	2151
1615	Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer. <b>2017</b> , 23, 4569-4577	65
1614	Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers. <b>2017</b> , 141, 851-861	64
1613	Small cell lung cancer transformation during immunotherapy with nivolumab: A case report. <b>2017</b> , 21, 52-55	18
1612	Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. <b>2017</b> , 22, 690-697	17
1611	Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. <b>2017</b> , 28, 1532-1539 <sup>167</sup>	
1610	Nivolumab induced myxedema crisis. <b>2017</b> , 5, 13	34
1609	Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. <b>2017</b> , 22, 700-708	9
1608	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. <b>2017</b> , 5, 417-424	241
1607	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. <b>2017</b> , 109, 1-8	19
1606	Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. <b>2017</b> , 28, 874-881	144
1605	Current status of research and treatment for non-small cell lung cancer in never-smoking females. <b>2017</b> , 18, 359-368	43
1604	Immune checkpoint inhibitors in lung cancer: an update. <b>2017</b> , 13, 955-959	4
1603	Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. <b>2017</b> , 152, 271-281	249
1602	Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities. <b>2017</b> , 18, 651-659	113
1601	Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?. <b>2017</b> , 79, 149-151	8
1600	Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. <b>2017</b> , 133, 561-569	35

1599	Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs. <b>2017</b> , 18, e363-e365	10
1598	Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer. <b>2017</b> , 12, 1085-1097	128
1597	PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. <b>2017</b> , 9, 499-506	122
1596	Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. <b>2017</b> , 9, 507-520	8
1595	Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. <b>2017</b> , 429, 1767-1786	12
1594	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. <b>2017</b> , 77, 3540-3550	213
1593	Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. <b>2017</b> , 317, 1844-1853	211
1592	Human papillomavirus type 16 E6 oncoprotein promotes proliferation and invasion of non-small cell lung cancer cells through Toll-like receptor 3 signaling pathway. <b>2017</b> , 89, 1852-1860	2
1591	Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. <b>2017</b> , 6, e1320626	47
1590	AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. <b>2017</b> , 195, 1150-1160	57
1589	Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. <b>2017</b> , 28, 1996-2001	150
1588	Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. <b>2017</b> , 77, 2318-2327	153
1587	Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. <b>2017</b> , 133, 331-338	77
1586	Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <b>2017</b> , 28, 1605-1611	324
1585	Efficacy and safety of osimertinib in a Japanese compassionate use program. <b>2017</b> , 47, 625-629	9
1584	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. <b>2017</b> , 123, 3285-3290	106
1583	Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient. <b>2017</b> , 12, e51-e55	2
1582	Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis. <b>2017</b> , 16, 1588-1595	16

1581	Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. <b>2017</b> , 26, 1139-1145	52
1580	Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome. <b>2017</b> , 133, 277-285	32
1579	Dysfunctional T cell metabolism in the tumor microenvironment. <b>2017</b> , 35, 7-14	59
1578	The next generation of immunotherapy: keeping lung cancer in check. <b>2017</b> , 10, 87	63
1577	An update on larynx cancer. <b>2017</b> , 67, 31-50	274
1576	Immunotherapy in Lung Cancer. <b>2017</b> , 31, 131-141	26
1575	Systemic Treatment of Brain Metastases. <b>2017</b> , 31, 157-176	6
1574	Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study. <b>2017</b> , 4, e67-e73	45
1573	Lung Cancer Biomarkers. <b>2017</b> , 31, 13-29	104
1572	Next-Generation Sequencing of Lung Cancers: Lessons Learned and Future Directions. <b>2017</b> , 31, 1-12	10
1571	The safety of nivolumab for the treatment of advanced non-small cell lung cancer. <b>2017</b> , 16, 101-109	6
1570	Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer. <b>2017</b> , 31, 31-44	6
1569	Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies. <b>2017</b> , 140, 1609-1619	11
1568	Raising the bar on first-line immunotherapy in lung cancer. <b>2017</b> , 18, 2-3	3
1567	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. <b>2017</b> , 18, 31-41	605
1566	PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. <b>2017</b> , 12, 208-222	812
1565	Real-world data on nivolumab treatment of non-small cell lung cancer. <b>2017</b> , 56, 438-440	36
1564	The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy. <b>2017</b> , 93, 1-14	6

1563	Diffuse pseudoprogession in a patient with metastatic non-small-cell lung cancer treated with Nivolumab. <b>2017</b> , 28, 2040-2041	19
1562	PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. <b>2017</b> , 23, 3158-3167	301
1561	Relationship of the Breast Ductal Carcinoma Immune Microenvironment with Clinicopathological and Genetic Features. <b>2017</b> , 23, 5210-5217	41
1560	The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. <b>2017</b> , 14, 1248-1260	10
1559	Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis. <b>2017</b> , 3, e171029	46
1558	Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?. <b>2017</b> , 125, 591-593	3
1557	Granuloma-forming interstitial pneumonia induced by nivolumab: a possible immune-related adverse event of the lung. <b>2017</b> , 6, 131-134	2
1556	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. <b>2017</b> , 153, 812-826	371
1555	PD-L1 Expression in Pancreatic Cancer. <b>2017</b> , 109,	26
1554	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. <b>2017</b> , 12, 563-569	50
1553	Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy. <b>2017</b> , 38, 223-232	23
1552	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. <b>2017</b> , 57, 36-49	185
1551	Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. <b>2017</b> , 22, 963-971	96
1550	Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. <b>2017</b> , 28, 2002-2008	108
1549	Immune Signatures of Non-Small Cell Lung Cancer. <b>2017</b> , 12, 913-915	4
1548	Immunogenomics: using genomics to personalize cancer immunotherapy. <b>2017</b> , 471, 209-219	5
1547	Advancing Immunotherapy in Metastatic Breast Cancer. <b>2017</b> , 18, 35	12
1546	Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy. <b>2017</b> , 22, 737-742	56



1545	Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 2483-2485	59.2	22
1544	First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 2415-2426	59.2	1474
1543	Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. <b>2017</b> , 6, e1339856		6
1542	The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. <b>2017</b> , 28, 2256-2263		54
1541	Clinical development of immunotherapy for prostate cancer. <b>2017</b> , 24, 675-680		5
1540	Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. <b>2017</b> , 58, 70-76		173
1539	Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. <b>2017</b> , 153, 1107-1119.e10		201
1538	PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. <b>2017</b> , 28, 882-889		77
1537	CD45RAFoxp3 regulatory T cells have a negative impact on the clinical outcome of head and neck squamous cell carcinoma. <b>2017</b> , 66, 1275-1285		29
1536	Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. <b>2017</b> , 12, 301-308		47
1535	Immunological effect of local ablation combined with immunotherapy on solid malignancies. <b>2017</b> , 36, 49		16
1534	Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. <b>2017</b> , 38, 577-593		190
1533	Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?. <b>2017</b> , 18, 33		9
1532	Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer. <b>2017</b> , 18, 36		14
1531	Programmed cell death-1/Programmed cell death ligand-1(PD-1/PD-L1) inhibitors, heralding a new era of immunotherapy in the management of advanced Non-Small Cell Lung Cancer (NSCLC). <b>2017</b> , 12, 6-13		8
1530	Checkpoint inhibitors for the treatment of non-small-cell lung cancer: news from the 2016 European Society for Medical Oncology Annual Congress. <b>2017</b> , 33, 126-132		1
1529	DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel. <b>2017</b> , 110, 26-31		44
1528	Combining radiotherapy with immunotherapy: the past, the present and the future. <b>2017</b> , 90, 20170157		60

1527	Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study. <b>2017</b> , 27, 894-901	86
1526	Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, -glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. <b>2017</b> , 16, 1705-1717	36
1525	Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review. <b>2017</b> , 17, 725-736	15
1524	An Introduction to Immunotherapy in the Treatment of Brain Tumors. <b>2017</b> , 1-10	
1523	Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. <b>2017</b> , 99, 153-164	52
1522	Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody. <b>2017</b> , 109, 74-77	13
1521	Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. <b>2017</b> , 25, 453-459	109
1520	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. <b>2017</b> , 18, 719-723	10
1519	Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials. <b>2017</b> , 49, 85-94	21
1518	Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer. <b>2017</b> , 108, 853-858	34
1517	High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes. <b>2017</b> , 3,	16
1516	Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. <b>2017</b> , 34, 121	11
1515	Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma. <b>2017</b> , 7, 555-557	8
1514	Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancer. <b>2017</b> , 35, 848-850	9
1513	Understanding the checkpoint blockade in lung cancer immunotherapy. <b>2017</b> , 22, 1266-1273	36
1512	Scientific Advances in Thoracic Oncology 2016. <b>2017</b> , 12, 1183-1209	29
1511	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. <b>2017</b> , 9, 579-587	10
1510	Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. <b>2017</b> , 123, 3807-3815	99

1509	Pembrolizumab-induced pneumonitis. <b>2017</b> , 3,	26
1508	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. <b>2017</b> , 22, 627-630	49
1507	Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. <b>2017</b> , 17, 647-655	10
1506	Addressing the quality of the ESMO-MCBS. <b>2017</b> , 28, 1406	8
1505	New insights into the role of EMT in tumor immune escape. <b>2017</b> , 11, 824-846	180
1504	Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types. <b>2017</b> , 18, 556-557	18
1503	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. <b>2017</b> , 18, 599-610	215
1502	Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma. <b>2017</b> , 103, 1750-1757	22
1501	Highlights on immune checkpoint inhibitors in non-small cell lung cancer. <b>2017</b> , 39, 1010428317695013	15
1500	Drug-biomarker co-development in oncology - 20 years and counting. <b>2017</b> , 30, 48-62	38
1499	Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient. <b>2017</b> , 12, e33-e34	0
1498	Update on cholangiocarcinoma: potential impact of genomic studies on clinical management. <b>2017</b> , 55, 575-581	20
1497	Promising immunotherapies for esophageal cancer. <b>2017</b> , 17, 723-733	16
1496	Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. <b>2017</b> , 19, 1047-1057	215
1495	Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab. <b>2017</b> , 31, 1048-1051	61
1494	Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment. <b>2017</b> , 8, 275-277	12
1493	Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma". <b>2017</b> , 23, 1629-1637	33
1492	Milestones in the systemic treatment of lung cancer. <b>2017</b> , 10, 22-26	6

1491	Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. <b>2017</b> , 18, 559-564	8
1490	Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment. <b>2017</b> , 108, 7-8	6
1489	Case report of nivolumab-related pneumonitis. <b>2017</b> , 9, 313-318	5
1488	Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. <b>2017</b> , 995, 97-125	69
1487	Computed Tomography Features of Lung Adenocarcinomas With Programmed Death Ligand 1 Expression. <b>2017</b> , 18, e375-e383	15
1486	Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. <b>2017</b> , 46, 210-219	71
1485	Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. <b>2017</b> , 15, 55	43
1484	Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. <b>2017</b> , 3, 974-978	49
1483	Overview of Basic Immunology for Clinical Investigators. <b>2017</b> , 995, 1-31	4
1482	Development of CAR T cells designed to improve antitumor efficacy and safety. <b>2017</b> , 178, 83-91	67
1481	Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients. <b>2017</b> , 7, 45124	49
1480	Liquid Biopsies in Solid Tumors. <b>2017</b> ,	
1479	PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. <b>2017</b> , 66, 865-876	94
1478	PD-L1 expression in neuroendocrine tumors of the lung. <b>2017</b> , 108, 115-120	81
1477	Prospects and progress of atezolizumab in non-small cell lung cancer. <b>2017</b> , 17, 781-789	11
1476	Pembrolizumab for the treatment of non-small cell lung cancer. <b>2017</b> , 17, 399-409	24
1475	Strategies for Increasing Pancreatic Tumor Immunogenicity. <b>2017</b> , 23, 1656-1669	92
1474	Cancer immunotherapies targeting the PD-1 signaling pathway. <b>2017</b> , 24, 26	332

1473	Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient. <b>2017</b> , 28, 1405-1406	8
1472	Cytokine-induced senescence for cancer surveillance. <b>2017</b> , 36, 357-365	7
1471	Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab. <b>2017</b> , 47, 463-466	43
1470	High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival. <b>2017</b> , 141, 184-190	4
1469	Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. <b>2017</b> , 34, 331-357	6
1468	Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. <b>2017</b> , 23, 4242-4250	513
1467	Detecting and Monitoring Circulating Stromal Cells from Solid Tumors Using Blood-Based Biopsies in the Twenty-First Century: Have Circulating Stromal Cells Come of Age?. <b>2017</b> , 81-104	2
1466	Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. <b>2017</b> , 31, 476-485	86
1465	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. <b>2017</b> , 16, 573-585	16
1464	Immunotherapy for gastric cancers: emerging role and future perspectives. <b>2017</b> , 10, 609-619	26
1463	Comorbidities in the management of patients with lung cancer. <b>2017</b> , 49,	42
1462	Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment. <b>2017</b> , 9, 451-460	9
1461	Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. <b>2017</b> , 20, 185-204	309
1460	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. <b>2017</b> , 18, 587-598	194
1459	Recognizing and managing on toxicities in cancer immunotherapy. <b>2017</b> , 39, 1010428317694542	22
1458	Urethral Cancer. <b>2017</b> , 54-67	
1457	Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. <b>2017</b> , 18, 631-639	247
1456	Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient. <b>2017</b> , 108, 72-74	21

1455	Immune checkpoint inhibition and its relationship with hypermutation phenotype as a potential treatment for Glioblastoma. <b>2017</b> , 132, 359-372	7
1454	[Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma]. <b>2017</b> , 58, 409-423	1
1453	Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. <b>2017</b> , 18, 595-606	34
1452	Immune Checkpoint Inhibitors in Gliomas. <b>2017</b> , 19, 23	21
1451	Mechanisms of Resistance to Immune Checkpoint Antibodies. <b>2018</b> , 249, 109-128	21
1450	The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. <b>2017</b> , 76, 167-182	182
1449	Metastatic clival chordoma: a case report of multiple extraneural metastases following resection and proton beam radiotherapy in a 5-year old boy. <b>2017</b> , 19, 531-537	1
1448	Immunotherapy. <b>2017</b> ,	4
1447	PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8 tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot staining. <b>2017</b> , 22, 726-733	38
1446	Radiation and Immune Checkpoint Blockade: From Bench to Clinic. <b>2017</b> , 27, 289-298	28
1445	Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. <b>2017</b> , 5, 12	121
1444	Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. <b>2017</b> , 35, 529-536	90
1443	Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape. <b>2017</b> , 12, 943-953	88
1442	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. <b>2017</b> , 18, 52-62	164
1441	T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. <b>2017</b> , 140, 2535-2544	30
1440	PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. <b>2017</b> , 140, 1384-1395	26
1439	Current progress in immunotherapy of hepatocellular carcinoma. <b>2017</b> , 66, 482-484	36
1438	Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. <b>2017</b> , 28, 583-589	348

1437	Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. <b>2017</b> , 28, 671-672	59
1436	Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment. <b>2017</b> , 9, 5-8	18
1435	Immuno-Oncology: The Third Paradigm in Early Drug Development. <b>2017</b> , 12, 125-138	16
1434	Targeted Therapies for Ovarian Cancer. <b>2017</b> , 41, 139-152	53
1433	Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. <b>2017</b> , 103, 44-51	56
1432	Characterization of TAP Ambr 250 disposable bioreactors, as a reliable scale-down model for biologics process development. <b>2017</b> , 33, 478-489	41
1431	Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma. <b>2017</b> , 6, 40-48	53
1430	Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. <b>2017</b> , 19, i1-i24	122
1429	Molecular approaches for classifying endometrial carcinoma. <b>2017</b> , 145, 200-207	88
1428	Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. <b>2017</b> , 18, 1-4	6
1427	Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). <b>2017</b> , 18, 333-339	32
1426	Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base. <b>2017</b> , 18, 286-292	34
1425	Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients. <b>2017</b> , 6, e1260214	5
1424	Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity. <b>2017</b> , 110, 1-12	50
1423	Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications. <b>2017</b> , 9, 46-58	26
1422	Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <b>2017</b> , 29, 218-230	37
1421	Pharmacological and immunological targeting of tumor mesenchymalization. <b>2017</b> , 170, 212-225	13
1420	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM. <b>2017</b> , 15, 31-41.e4	28

1419	Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. <b>2017</b> , 41, 111-124	30
1418	Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. <b>2017</b> , 23, 3012-3024	442
1417	Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. <b>2017</b> , 35, 243-252	15
1416	Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model. <b>2017</b> , 487, 1-7	25
1415	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. <b>2017</b> , 49, 141-155	68
1414	Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. <b>2017</b> , 16, 264-272	127
1413	Immunological profiling of molecularly classified high-risk endometrial cancers identifies -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. <b>2017</b> , 6, e1264565	79
1412	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. <b>2017</b> , 76, 43-50	248
1411	Evaluation of HLA-G, HLA-E, and PD-L1 proteins in oral osteosarcomas. <b>2017</b> , 123, e188-e196	17
1410	Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. <b>2017</b> , 69, 1751-1763	216
1409	Whole-exome sequencing predicted cancer epitope trees of 23 early cervical cancers in Chinese women. <b>2017</b> , 6, 207-219	7
1408	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <b>2017</b> , 389, 255-265	2681
1407	Programmed death of chemotherapy in non-small-cell lung cancer?. <b>2017</b> , 389, 227-228	4
1406	Emerging biomarkers for PD-1 pathway cancer therapy. <b>2017</b> , 11, 53-67	9
1405	The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. <b>2017</b> , 104, 7-15	54
1404	High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases. <b>2017</b> , 67, 37-44	24
1403	Innate immune signaling and regulation in cancer immunotherapy. <b>2017</b> , 27, 96-108	205
1402	Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non-Small Cell Lung Cancer. <b>2017</b> , 77, 851-861	35



1401	Chemotherapy enhances programmed cell death <sup>1</sup> /ligand <sup>1</sup> expression via TGF- $\beta$ -induced epithelial mesenchymal transition in non-small cell lung cancer. <b>2017</b> , 38, 2277-2284	22
1400	Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient. <b>2017</b> , 40, 621-622	23
1399	Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells. <b>2017</b> , 14, 5563-5568	2
1398	[Personalized therapy of lung cancer - current standard and future challenges]. <b>2017</b> , 142, 1660-1668	0
1397	Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer. <b>2017</b> , 80, 1189-1196	5
1396	The clinical development of vaccines for HER2 breast cancer: Current landscape and future perspectives. <b>2017</b> , 61, 107-115	21
1395	Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis. <b>2017</b> , 16, 301-308	4
1394	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. <b>2017</b> , 111, 108-115	11
1393	S-1 as an option for second-line treatment of NSCLC. Is the 'East Side Story' applicable in the West?. <b>2017</b> , 28, 2627-2629	0
1392	Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. <b>2017</b> , 12, 1798-1805	241
1391	Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas. <b>2017</b> , 113, 93-101	21
1390	PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung. <b>2017</b> , 51, 357-362	28
1389	Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. <b>2017</b> , 2, e000236	19
1388	Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. <b>2017</b> , 3, 1692-1696	113
1387	Current challenges in the management of follicular lymphoma. <b>2017</b> , 6, 13-24	1
1386	Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors: a systematic review. <b>2017</b> , 9, 995-1004	10
1385	Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on F-fluorodeoxyglucose positron emission tomography/computed tomography. <b>2017</b> , 6, 2552-2561	58
1384	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <b>2017</b> , 390, 2461-2471	1123

1383	Frontiers in Ovarian Cancer Science. <b>2017</b> ,	1
1382	PD-L1 IHC in NSCLC with a global and methodological perspective. <b>2017</b> , 113, 102-105	25
1381	Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition. <b>2017</b> , 7, 7958	31
1380	Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. <b>2017</b> , 23, 7474-7482	40
1379	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. <b>2017</b> , 119, 30-39	29
1378	Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma. <b>2017</b> , 86, 15-27	44
1377	Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. <b>2017</b> , 119, 1-12	105
1376	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. <b>2017</b> , 7, 1420-1435	302
1375	PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. <b>2017</b> , 125, 896-907	119
1374	Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune. <b>2017</b> , 96, 378-383	55
1373	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. <b>2017</b> , 17, 1055-1069	19
1372	Racial/ethnic disparities: need more work!. <b>2017</b> , 130, 1685-1686	2
1371	[Lung cancer : What has been confirmed in therapy?]. <b>2017</b> , 58, 1258-1263	1
1370	Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice. <b>2017</b> , 62, 374-380	9
1369	Investigational PD-1 inhibitors for advanced non-small lung cancer: new players in a shifting paradigm. <b>2017</b> , 26, 1317-1319	6
1368	Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer. <b>2017</b> , 3, 360-373	7
1367	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. <b>2017</b> , 86, 257-265	21
1366	ESMO-Magnitude of Clinical Benefit Scale version 1.1. <b>2017</b> , 28, 2340-2366	266

1365	Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). <b>2017</b> , 28, 2698-2706 <sup>51</sup>	
1364	Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. <b>2017</b> , 28, 3015-3021	52
1363	Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer. <b>2017</b> , 21, 211-220	2
1362	Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas. <b>2017</b> , 141, 1529-1532	15
1361	Cancer: Towards a general theory of the target: All successful cancer therapies, actual or potential, are reducible to either (or both) of two fundamental strategies. <b>2017</b> , 39, 1700059	2
1360	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. <b>2017</b> , 16, 2598-2608	1183
1359	Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro. <b>2017</b> , 38, 1877-1885	18
1358	Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors. <b>2017</b> , 104, e217-e218	40
1357	Immunotherapy for Non-Small Cell Lung Cancer: A Therapy for All Stages?. <b>2017</b> , 29, 416-417	
1356	Nivolumab-induced asthma in a patient with non-small-cell lung cancer. <b>2017</b> , 28, 2891	12
1355	Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. <b>2017</b> , 18, 1477-1490	16
1354	Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. <b>2017</b> , 11, 353-373	19
1353	Nivolumab-associated nausea and vomiting as an immune adverse event. <b>2017</b> , 84, 367-369	7
1352	Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses. <b>2017</b> , 109,	18
1351	Radiotherapy in combination with immune checkpoint inhibitors. <b>2017</b> , 29, 105-111	12
1350	Severe acute interstitial lung disease after nivolumab in three non-small cell lung cancer patients with imaging findings of airway obstruction adjacent to lung tumors. <b>2017</b> , 23, 826-829	11
1349	Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?. <b>2017</b> , 27, 566-571	9
1348	New Immunotherapy and Lung Cancer. <b>2017</b> , 53, 682-687	6

1347	Lung Cancer in the Older Patient. <b>2017</b> , 33, 563-577		13
1346	Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. <b>2017</b> , 32, 1-15		76
1345	Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab. <b>2017</b> , 12, e140-e141		35
1344	PDL-1/PD1 inhibitors: antibody or antinobody?. <b>2017</b> , 13, 1669-1671		7
1343	Bevacizumab in advanced lung cancer: state of the art. <b>2017</b> , 13, 2515-2535		33
1342	Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings. <b>2017</b> , 6, 169-174		10
1341	Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 849-861	59.2	376
1340	Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers. <b>2017</b> , 9, 767-780		8
1339	Prognostic value of tumor PD-L1 expression combined with CD8 tumor infiltrating lymphocytes in high grade serous ovarian cancer. <b>2017</b> , 52, 7-14		49
1338	Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. <b>2017</b> , 117, 913-920		111
1337	The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions. <b>2017</b> , 12, 709-718		13
1336	Tumour radiosensitivity is associated with immune activation in solid tumours. <b>2017</b> , 84, 304-314		27
1335	Trial watch: Immune checkpoint blockers for cancer therapy. <b>2017</b> , 6, e1373237		53
1334	A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002). <b>2017</b> , 80, 955-963		10
1333	Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients. <b>2017</b> , 44, 1080-1086		37
1332	Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer. <b>2017</b> , 23, 5394-5405		48
1331	Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. <b>2017</b> , 9, 913-927		24
1330	Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer. <b>2017</b> , 85, 155-157		5

1329	Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. <b>2017</b> , 57 Suppl 10, S26-S42	63
1328	Nanomaterials for cancer immunotherapy. <b>2017</b> , 148, 16-30	173
1327	Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor. <b>2017</b> , 6, 2347-2356	35
1326	Nucleobase-modified polyamidoamine-mediated miR-23b delivery to inhibit the proliferation and migration of lung cancer. <b>2017</b> , 5, 2268-2275	19
1325	Immune cell profiling in cancer: molecular approaches to cell-specific identification. <b>2017</b> , 1, 26	42
1324	Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation. <b>2017</b> , 410, 3-27	36
1323	Évaluation thérapeutique des tumeurs solides à l'échelle de la session 6. <b>2017</b> , 41, 367-370	
1322	Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?. <b>2017</b> , 60, 60-68	83
1321	PD-1 checkpoint inhibition: Toxicities and management. <b>2017</b> , 35, 701-707	44
1320	Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. <b>2017</b> , 7, 11373	42
1319	Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib. <b>2017</b> , 13, 2629-2644	7
1318	Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. <b>2017</b> , 9, 797-804	23
1317	A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition. <b>2017</b> , 14,	64
1316	Role of PD-1 in Immunity and Diseases. <b>2017</b> , 410, 75-97	85
1315	Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. <b>2017</b> , 50, 185-194	21
1314	Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. <b>2017</b> , 35, 1195-1209	14
1313	The Challenge for Development of Valuable Immuno-oncology Biomarkers. <b>2017</b> , 23, 4970-4979	54
1312	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. <b>2017</b> , 23, 4959-4969	71

1311	Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. <b>2017</b> , 23, 4992-5002	26
1310	Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease. <b>2017</b> , 7, 604-608	12
1309	A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. <b>2017</b> , 73, 138-146	61
1308	An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma. <b>2017</b> , 22, 213-222	5
1307	Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536. <b>2017</b> , 40, 435-439	7
1306	PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. <b>2017</b> , 7, 10255	110
1305	Neurological Complications of Immunotherapies-Beware of the Checkpoint Ahead. <b>2017</b> , 74, 1176-1177	1
1304	Case series of pleomorphic carcinomas of the lung treated with nivolumab. <b>2017</b> , 8, 724-728	35
1303	Atezolizumab for the treatment of non-small cell lung cancer. <b>2017</b> , 10, 935-945	21
1302	Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. <b>2017</b> , 77, 527-533	35
1301	Racial and ethnic disparities in hematologic malignancies. <b>2017</b> , 130, 1699-1705	60
1300	Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer. <b>2017</b> , 111, 182-189	20
1299	Cancer Immunotherapy in Older Patients. <b>2017</b> , 23, 219-222	14
1298	The Biology of Aging and Cancer: Frailty, Inflammation, and Immunity. <b>2017</b> , 23, 201-205	43
1297	Nivolumab-induced autoimmune diabetes. <b>2017</b> , 47, 136-139	3
1296	Lung cancer as a paradigm for precision oncology in solid tumours. <b>2017</b> , 471, 221-233	10
1295	Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. <b>2017</b> , 59, 71-78	65
1294	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <b>2017</b> , 7, 1088-1097	105

1293	Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. <b>2017</b> , 80, 591-598	34
1292	Immunotherapy targeting immune check-point(s) in brain metastases. <b>2017</b> , 36, 33-38	7
1291	Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review. <b>2017</b> , 14, 1568-1580	8
1290	Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India. <b>2017</b> , 31, 56-61	12
1289	The immune contexture in cancer prognosis and treatment. <b>2017</b> , 14, 717-734	935
1288	Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. <b>2017</b> , 11, 1238-1246	79
1287	Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. <b>2017</b> , 13, 277-288	31
1286	Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. <b>2017</b> , 13, 296-303	12
1285	C�ncer de pulm�n no microc�tico. <b>2017</b> , 12, 1811-1824	
1284	[Current knowledge on perioperative treatments of non-small cell lung carcinomas]. <b>2017</b> , 34, 618-634	5
1283	Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. <b>2017</b> , 44, 132-135	64
1282	A novel bifunctional anti-PD-L1/TGF-�trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. <b>2017</b> , 6, e1349589	91
1281	Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study. <b>2017</b> , 108, 1223-1230	47
1280	CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. <b>2017</b> , 66, 1449-1461	38
1279	[What is the place of the combinations for immunotherapy with chemotherapy or with other immune checkpoint inhibitors?]. <b>2017</b> , 104, 485-493	1
1278	Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy. <b>2017</b> , 83, 28-31	27
1277	Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade. <b>2017</b> , 141, 1891-1900	20
1276	Cancer Immunotherapies: Are They as Effective in the Elderly?. <b>2017</b> , 34, 567-581	22

1275	Regulation of immune-related diseases by multiple factors of chromatin, exosomes, microparticles, vaccines, oxidative stress, dormancy, protein quality control, inflammation and microenvironment: a meeting report of 2017 International Workshop of the Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine on Tumor Immunology. <b>2017</b> , 7, 532-540	3
1274	Immunohistochemical investigations on the expression of programmed cell death ligand 1, human leukocyte antigens G and E, and granzyme B in intraoral mucoepidermoid carcinoma. <b>2017</b> , 83, 55-62	15
1273	Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. <b>2017</b> , 111, 6-11	2
1272	The "value" of immune-checkpoint inhibitors for advanced lung cancer. <b>2017</b> , 55, 253-254	
1271	EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. <b>2017</b> , 6, e1356145	177
1270	Immunotherapy: Who Is Eligible?. <b>2017</b> , 50, 867-874	4
1269	Clinical and palliative care outcomes for patients of poor performance status treated with anti-programmed death-1 monoclonal antibodies for advanced melanoma. <b>2017</b> , 13, 385-390	24
1268	Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District. <b>2017</b> , 47, 1405-1411	9
1267	Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment. <b>2017</b> , 50,	12
1266	Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. <b>2017</b> , 19, 62	11
1265	Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. <b>2017</b> , 111, 176-181	370
1264	Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression. <b>2017</b> , 28, 186-189	13
1263	Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice. <b>2017</b> , 125, 521-528	7
1262	Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab. <b>2017</b> , 2, e000145	9
1261	Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge. <b>2017</b> , 83, 266-278	16
1260	Checkpoint inhibitors in the treatment of urological malignancies. <b>2017</b> , 2, e000165	15
1259	Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non-Small Cell Lung Cancer. <b>2017</b> , 12, 1733-1736	2
1258	Precision regimen for personalized pancreatic cancer therapy. <b>2017</b> , 1, 44-45	



1257	Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer. <b>2017</b> , 12, 1536-1543	41
1256	Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. <b>2017</b> , 2, e000200	25
1255	Prädiktive molekulare Marker als therapeutische Weichensteller beim nichtkleinzelligen Lungenkarzinom. <b>2017</b> , 32, 307-311	
1254	Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer. <b>2017</b> , 29, 97-104	29
1253	The importance for immunoregulation for long-term cancer control. <b>2017</b> , 13, 1619-1632	8
1252	Lung cancer as a cardiotoxic state: a review. <b>2017</b> , 34, 159	7
1251	Immunotherapy in Non-Small Cell Lung Cancer Treatment: Current Status and the Role of Imaging. <b>2017</b> , 32, 300-312	35
1250	Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. <b>2017</b> , 117, 921-924	52
1249	Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer. <b>2017</b> , 2, e000102	7
1248	Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics. <b>2017</b> , 13, 1649-1663	6
1247	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. <b>2017</b> , 44, 2310-2325	34
1246	Recent Advances in Targeting ROS1 in Lung Cancer. <b>2017</b> , 12, 1611-1625	132
1245	Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014. <b>2017</b> , 123, 4672-4679	11
1244	The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. <b>2017</b> , 5, 767-777	69
1243	Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies. <b>2017</b> , 12, 571-597	97
1242	Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives. <b>2017</b> , 59, 109-116	83
1241	Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. <b>2017</b> , 50,	192
1240	[Clinical pharmacology and immunotherapy, 4th edition of the congress of pharmacology of anticancer drugs]. <b>2017</b> , 104, 807-811	0

1239	Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. <b>2017</b> , 112, 90-95	128
1238	PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. <b>2017</b> , 112, 200-215	122
1237	Concurrence of nivolumab-induced interstitial lung disease and cancer invasion. <b>2017</b> , 5, e00257	7
1236	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. <b>2017</b> , 19, 64	71
1235	Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context. <b>2017</b> , 13 Suppl 3, 3-13	10
1234	Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma. <b>2017</b> , 57, 1527-1533	22
1233	EGFR tyrosine kinase inhibitors chemotherapy in wild-type pre-treated advanced nonsmall cell lung cancer in 'daily practice. <b>2017</b> , 50,	12
1232	MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. <b>2017</b> , 6, e1338998	28
1231	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Metastatic Tumors. <b>2017</b> , 24, 311-335	299
1230	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <b>2017</b> , 24, 235-251	293
1229	Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. <b>2017</b> , 28, 2377-2385	372
1228	Oncogenic RAS Signaling Promotes Tumor Immuno-resistance by Stabilizing PD-L1 mRNA. <b>2017</b> , 47, 1083-1099. e61	61
1227	Immunotherapy of Cancer. <b>2017</b> , 244-266	
1226	[Current Aspects of Diagnosis and Treatment of Lung Cancer]. <b>2017</b> , 142, 1808-1812	3
1225	Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support. <b>2017</b> , 16, 2645-2655	39
1224	New Immunotherapy and Lung Cancer. <b>2017</b> , 53, 682-687	3
1223	DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. <b>2017</b> , 8, 1751	300
1222	Quality matters: immunotherapy and the evolving landscape of advanced cancer care. <b>2017</b> , 2, 235-244	2

1221	Targeting immune checkpoints in breast cancer: an update of early results. <b>2017</b> , 2, e000255	79
1220	Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non-Small Cell Lung Cancer Tissue. <b>2017</b> , 12, 1177271917699850	2
1219	Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. <b>2017</b> , 171, 1284-1300.e21	215
1218	De-novo and acquired resistance to immune checkpoint targeting. <b>2017</b> , 18, e731-e741	383
1217	Personalised medicine for nonsmall cell lung cancer. <b>2017</b> , 26,	28
1216	Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis. <b>2017</b> , 2, e000119	6
1215	Treatment of Recurrent Epithelial Ovarian Cancer. <b>2017</b> , 243-265	
1214	Cancer immunotherapy: The dark side of PD-1 receptor inhibition. <b>2017</b> , 552, 41-42	25
1213	Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1986-1988	59.2 31
1212	[Autoimmune reactions to immune checkpoint inhibitors]. <b>2017</b> , 76, 57-62	1
1211	Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer. <b>2017</b> , 86, 349-357	59
1210	Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. <b>2017</b> , 13, 755-763	95
1209	Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD-L1 (CD274)-expression: Possible roles of tumour micro environmental factors for CD274 expression. <b>2017</b> , 3, 268-278	13
1208	What's new in chemotherapy for non-small cell lung cancer?. <b>2017</b> , 10, 123-126	
1207	Cardiotoxicity of immune checkpoint inhibitors. <b>2017</b> , 2, e000247	126
1206	Live Cell Labeling with Terpyridine Derivative Proligands to Measure Cytotoxicity Mediated by Immune Cells. <b>2017</b> , 12, 2006-2013	6
1205	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. <b>2017</b> , 18, 1600-1609	185
1204	Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response. <b>2017</b> , 12, e182-e184	24

1203	Adherence to surveillance guidelines in resected NSCLC: Physician compliance and impact on outcomes. <b>2017</b> , 112, 176-180	1
1202	Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis. <b>2017</b> , 96, e8407	8
1201	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <b>2017</b> , 18, 1104-1115	232
1200	Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope. <b>2017</b> , 19, 49	15
1199	New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. <b>2017</b> , 23, 10-22	35
1198	Checkpointinhibitoren. <b>2017</b> , 23, 619-625	
1197	Overall survival and prognostic factors in patients with spinal metastases from lung cancer treated with and without epidermal growth factor receptor tyrosine kinase inhibitors. <b>2017</b> , 22, 698-705	7
1196	Immune checkpoint inhibitors and elderly people: A review. <b>2017</b> , 82, 155-166	99
1195	Targeted therapies for renal cell carcinoma. <b>2017</b> , 13, 496-511	127
1194	Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer: everyday clinical practice in a single centre. <b>2017</b> , 28, 654-659	2
1193	Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. <b>2017</b> , 111, 65-68	13
1192	Intratumor heterogeneity of immune checkpoints in primary renal cell cancer: Focus on HLA-G/ILT2/ILT4. <b>2017</b> , 6, e1342023	24
1191	Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial. <b>2017</b> , 13, 1893-1905	8
1190	Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. <b>2017</b> , 12, 475-485	23
1189	Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. <b>2017</b> , 17, 779-786	24
1188	Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2017</b> , 28, iv119-iv142	1100
1187	Immune checkpoint inhibitors for patients with colorectal cancer: mismatch repair deficiency and perspectives. <b>2017</b> , 6, 23-31	1
1186	Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples. <b>2017</b> , 18, e473-e479	27

1185	PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges. <b>2017</b> , 405, 29-37	51
1184	Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical cases. <b>2017</b> , 81, 138-141	0
1183	Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. <b>2017</b> , 23, 5737-5744	55
1182	Combination Therapy with NHS-muLL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models. <b>2017</b> , 23, 5869-5880	34
1181	Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy. <b>2017</b> , 23, 5948-5958	66
1180	PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. <b>2017</b> , 66, 13-33	34
1179	What's new in small cell lung cancer - extensive disease? An overview on advances of systemic treatment in 2016. <b>2017</b> , 13, 1427-1435	4
1178	Biomarkers of response to PD-1/PD-L1 inhibition. <b>2017</b> , 116, 116-124	185
1177	Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions. <b>2017</b> , 5, 69-74	4
1176	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. <b>2017</b> , 14, 655-668	498
1175	Assessing treatment efficacy in the subset of responders in a randomized clinical trial. <b>2017</b> , 28, 1640-1647	2
1174	Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody. <b>2017</b> , 28, 2893-2895	39
1173	Optimale Therapie des nichtkleinzelligen Lungenkarzinoms im Stadium IIIB/C. <b>2017</b> , 20, 32-42	
1172	Spotlight on landmark oncology trials: the latest evidence and novel trial designs. <b>2017</b> , 15, 111	2
1171	Precision medicine in breast cancer: reality or utopia?. <b>2017</b> , 15, 139	38
1170	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. <b>2017</b> , 5,	8
1169	Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. <b>2017</b> , 5, 40	74
1168	Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. <b>2017</b> , 5, 46	49

1167	Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. <b>2017</b> , 5, 49	20
1166	Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. <b>2017</b> , 22, 1232-1237	87
1165	The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. <b>2017</b> , 9, 681-692	69
1164	Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review. <b>2017</b> , 9, 701-707	15
1163	Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. <b>2017</b> , 36, 5-15	33
1162	A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. <b>2017</b> , 111, 1-5	43
1161	PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. <b>2017</b> , 30, 1411-1421	114
1160	Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations. <b>2017</b> , 209, 567-575	22
1159	Immunotherapeutic Approaches to Biliary Cancer. <b>2017</b> , 18, 44	8
1158	Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series "Pathology for the clinician" Edited by Peter Dorfmler and Alberto Cavazza. <b>2017</b> , 26,	49
1157	Nivolumab-Induced Granulomatous Inflammation of the Pleura. <b>2017</b> , 12, e100-e101	5
1156	Immunchekpointinhibitoren. <b>2017</b> , 23, 575-584	
1155	PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. <b>2017</b> , 14, 203-220	250
1154	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. <b>2017</b> , 23, 1920-1928	698
1153	Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. <b>2017</b> , 22, 3-11	29
1152	EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. <b>2017</b> , 385, 51-54	128
1151	Molecular targets for HCC and future treatments. <b>2017</b> , 66, 234-235	5
1150	Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. <b>2017</b> , 12, 281-292	66

1149	Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. <b>2017</b> , 30, 340-349	105
1148	Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. <b>2017</b> , 17, 47-59	27
1147	Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. <b>2017</b> , 105, 383-386	49
1146	Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. <b>2017</b> , 119, 579-584	12
1145	New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?. <b>2017</b> , 18, 35-44	16
1144	Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. <b>2017</b> , 38, 25-40	62
1143	Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy. <b>2017</b> , 28, 434-435	10
1142	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. <b>2017</b> , 44, 158-176	135
1141	Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. <b>2017</b> , 28, 57-74	32
1140	Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy. <b>2017</b> , 24, 21-30	53
1139	Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. <b>2017</b> , 5, 42-50	201
1138	Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. <b>2017</b> , 18, 60-67	4
1137	Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. <b>2017</b> , 30, 278-285	59
1136	Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients. <b>2017</b> , 161, 51-62	5
1135	Cytological reporting on lung FNA and small biopsy specimens in the era of personalized medicine. <b>2017</b> , 125, 155-160	1
1134	Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials. <b>2017</b> , 140, 948-958	33
1133	Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?. <b>2017</b> , 13, 528-532	23
1132	Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment. <b>2017</b> , 64, e1-e3	11

1131	Antibody therapeutics for treating prostate cancer: where are we now and what comes next?. <b>2017</b> , 17, 135-149	4
1130	Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer. <b>2017</b> , 18, 132-140	15
1129	Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. <b>2017</b> , 44, 117-122	121
1128	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <b>2017</b> , 22, 81-88	95
1127	HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status. <b>2017</b> , 23, 825-832	51
1126	Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors. <b>2017</b> , 57, 394-400	38
1125	Lung cancer: current therapies and new targeted treatments. <b>2017</b> , 389, 299-311	1358
1124	CD137-CRDI is not necessary in the role of contacting its natural ligand. <b>2017</b> , 95, 24-32	3
1123	Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. <b>2017</b> , 20, 602-611	53
1122	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <b>2017</b> , 12, 194-207	132
1121	Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. <b>2017</b> , 28, 44-56	24
1120	Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol. <b>2017</b> , 18, 92-95	19
1119	Global chemotherapy development for gastric cancer. <b>2017</b> , 20, 92-101	24
1118	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. <b>2017</b> , 77, 123-144	4
1117	Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status. <b>2017</b> , 197, 690-697	58
1116	Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. <b>2017</b> , 28, 368-376	468
1115	Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. <b>2017</b> , 80, 7-14	28
1114	Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. <b>2017</b> , 18, 100-103	7



1113	Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach. <b>2017</b> , 18, 220-233.e8	60
1112	A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma. <b>2017</b> , 123, 576-582	27
1111	Immunotherapy Comes of Age in Lung Cancer. <b>2017</b> , 18, 13-22	49
1110	W'ALK' Into the Next Stage. <b>2017</b> , 18, 122-126	5
1109	Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). <b>2017</b> , 3, 827-831	347
1108	New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group. <b>2017</b> , 109, 35-41	12
1107	Comparison of exome-based HLA class I genotyping tools: identification of platform-specific genotyping errors. <b>2017</b> , 62, 397-405	31
1106	A consensus statement on the gender perspective in lung cancer. <b>2017</b> , 19, 527-535	16
1105	Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer. <b>2017</b> , 10, 31-38	16
1104	Immunotherapy approaches in the treatment of malignant brain tumors. <b>2017</b> , 123, 734-750	63
1103	Histopathologic diagnosis of brain metastases: current trends in management and future considerations. <b>2017</b> , 34, 8-19	15
1102	Next generation predictive biomarkers for immune checkpoint inhibition. <b>2017</b> , 36, 179-190	67
1101	The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. <b>2017</b> , 103, 27-37	89
1100	A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. <b>2017</b> , 28, 285-291	10
1099	Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology. <b>2017</b> , 43, 65-78	78
1098	The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer. <b>2017</b> , 68, 153-168	20
1097	Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors. <b>2017</b> , 13, 185-194	6
1096	Wnt signaling in cancer. <b>2017</b> , 36, 1461-1473	1238

1095	PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. <b>2017</b> , 12, 110-120	76
1094	Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. <b>2017</b> , 35, 709-717	587
1093	Nivolumab-Induced Colitis Treated by Infliximab. <b>2017</b> , 15, e80-e81	53
1092	Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. <b>2017</b> , 22, 70-80	41
1091	Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. <b>2017</b> , 109,	104
1090	Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis. <b>2017</b> , 32, e68-e74	47
1089	Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer. <b>2017</b> , 96, e9320	7
1088	Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials. <b>2017</b> , 96, e8931	17
1087	Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer. <b>2017</b> ,	78
1086	Commentary on Freidlin and Korn. <b>2017</b> , 14, 605-608	3
1085	Les cancers bronchiques non ^ petites cellules EGFR-mut�. <b>2017</b> , 9, 213-223	
1084	Characterization of Tumor Cells Using a Medical Wire for Capturing Circulating Tumor Cells: A 3D Approach Based on Immunofluorescence and DNA FISH. <b>2017</b> ,	4
1083	Prise en charge des patients de stade avanc� avec remaniement ALK : aujourd�hui et demain (« qui sera un autre jour... »). <b>2017</b> , 9, 224-233	
1082	Traitement de premi�re ligne et de maintenance dans les CBNPC avanc�s en l�absence d�addiction oncog�nique. <b>2017</b> , 9, 234-247	
1081	Cancer bronchique non ^ petites cellules de stade IV sans addiction oncog�nique : traitements en 2 e ligne et au-del�. <b>2017</b> , 9, 248-258	
1080	M�tastases c�brales des cancers bronchiques non ^ petites cellules (CBNPC). <b>2017</b> , 9, 271-287	
1079	Immunoth�rapie et cancer du poumon : o�n sommes-nous ?. <b>2017</b> , 9, 315-324	0
1078	Les complications de l�immunoth�rapie. <b>2017</b> , 9, 325-331	1

1077	Altfations molçulaires anciennes et émergentes : quand les rechercher ?. <b>2017</b> , 9, 202-212	
1076	Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. <b>2018</b> , 8, 310-314	16
1075	Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab. <b>2017</b> , 28, 3106-3107	12
1074	Les patients avec indice de performance supérieur ^1. <b>2017</b> , 9, 308-314	
1073	Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy. <b>2017</b> , 9, 769-779	9
1072	EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. <b>2017</b> , 28, iv84-iv99	157
1071	Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report. <b>2017</b> , 7, 988-990	12
1070	TNF $\beta$ blockade overcomes resistance to anti-PD-1 in experimental melanoma. <b>2017</b> , 8, 2256	175
1069	Outcomes after surgical resection of thymic carcinoma. <b>2017</b> , 31, 148-154	
1068	"Lazarus response" of nivolumab in a frail patient with non-small-cell lung cancer. <b>2017</b> , 5, e00247	4
1067	Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptor. <b>2018</b> , 15, 1549-1558	3
1066	Management immunvermittelter Nebenwirkungen. <b>2017</b> , 20, 54-64	
1065	Checkpointinhibitoren beim nichtkleinzelligen Lungenkarzinom. <b>2017</b> , 23, 838-844	
1064	Immuntherapie in der Onkologie. <b>2017</b> , 12, 17-33	1
1063	Why Did my Patient get this Kidney Problem after Receiving this New Cancer Drug?. <b>2017</b> , 1, 9-17	1
1062	PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. <b>2017</b> , 8, 58457-58468	35
1061	RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB. <b>2017</b> , 23, 1223-1231	16
1060	Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 ( <a href="http://www.esmo.org/Guidelines/Lung-and-Chest-Tumours">www.esmo.org/Guidelines/Lung-and-Chest-Tumours</a> ). <b>2017</b> , 28, iv158-iv161	

1059	Caring for the Older Population With Advanced Lung Cancer. <b>2017</b> , 37, 587-596	6
1058	Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 Therapy. <b>2017</b> , 1,	1
1057	The Biology of Aging and Cancer: Frailty, Inflammation, and Immunity. <b>2017</b> , 23, 201-205	21
1056	Cancer Immunotherapy in Older Patients. <b>2017</b> , 23, 219-222	4
1055	Clinical use of immune checkpoint inhibitors. <b>2017</b> ,	
1054	Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy. <b>2017</b> , 2017,	11
1053	Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor. <b>2017</b> , 8, 2681-2693	14
1052	A Case of Secondary Adrenocortical Insufficiency Developed due to ACTH Deficiency After Nivolumab Treatment. <b>2017</b> , 57, 226-231	0
1051	Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma. <b>2017</b> , 9, 741-750	14
1050	Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context. <b>2017</b> , 13, 223-236	15
1049	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. <b>2017</b> , 11, 787	24
1048	Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. <b>2017</b> , 8, 49	314
1047	Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. <b>2017</b> , 8, 730	233
1046	Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. <b>2017</b> , 13, 1259-1271	12
1045	Treating mutation resistance in non-small cell lung cancer - role of osimertinib. <b>2017</b> , 10, 49-56	18
1044	Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. <b>2017</b> , 9,	31
1043	Bevacizumab in the treatment of NSCLC: patient selection and perspectives. <b>2017</b> , 8, 259-269	25
1042	New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab. <b>2017</b> , 8, 67-78	20

1041	Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles. <b>2017</b> , 17, 378-391	50
1040	The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer. <b>2017</b> , 8, 57826-57835	21
1039	Beyond chemotherapy for advanced disease-the role of EGFR and PD-1 inhibitors. <b>2017</b> , 6, 848-854	6
1038	Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. <b>2017</b> , 6, 51-71	76
1037	Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. <b>2017</b> , 8, 1-11	6
1036	Immunotherapy Clinical Trials in Neuro-Oncology. <b>2017</b> , 181-210	
1035	Cost analysis of adverse events associated with non-small cell lung cancer management in France. <b>2017</b> , 9, 443-449	4
1034	PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. <b>2017</b> , 7, 1-11	29
1033	Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. <b>2017</b> , 18,	60
1032	CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. <b>2017</b> , 8, 269	34
1031	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. <b>2017</b> , 8, 1597	145
1030	Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. <b>2017</b> , 7, 3585-3594	127
1029	Immunotherapy for Pediatric Brain Tumors. <b>2017</b> , 7,	13
1028	Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung Cancer. <b>2017</b> , 9,	41
1027	Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. <b>2017</b> , 9,	15
1026	The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. <b>2017</b> , 18,	34
1025	Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. <b>2017</b> , 8, 961	70
1024	Natural Killer T Cell-Targeted Immunotherapy Mediating Long-term Memory Responses and Strong Antitumor Activity. <b>2017</b> , 8, 1206	10

1023	Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages. <b>2017</b> , 8, 1479	77
1022	Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer. <b>2017</b> , 4, 4	24
1021	Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms. <b>2017</b> , 4, 9	11
1020	Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib. <b>2017</b> , 4, 36	9
1019	The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer. <b>2017</b> , 7, 33	11
1018	Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. <b>2017</b> , 7, 50	21
1017	Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine. <b>2017</b> , 7, 52	22
1016	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. <b>2017</b> , 7, 67	25
1015	Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma. <b>2017</b> , 7, 141	14
1014	Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy. <b>2017</b> , 7, 197	18
1013	Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"?. <b>2017</b> , 7, 205	6
1012	Radiotherapy for Oligometastatic Lung Cancer. <b>2017</b> , 7, 210	26
1011	Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. <b>2017</b> , 7, 230	31
1010	Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future. <b>2017</b> , 2017, 1623679	5
1009	A Case of Nivolumab-Induced Severe Mononeuropathy Multiplex and Rhabdomyolysis. <b>2017</b> , 2017, 1093858	12
1008	Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. <b>2017</b> , 2017, 3145742	17
1007	Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer. <b>2017</b> , 2017, 6012810	9
1006	CD80 Expressed by CD8 T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8 T Cells. <b>2017</b> , 2017, 7659462	21

1005	Targeting the Pd-1 Pathway in Renal Cell Carcinoma: A Review. <b>2017</b> , 1, 179-187	1
1004	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. <b>2017</b> , 2017, 5618174	8
1003	Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer. <b>2017</b> , 2017, 1423683	8
1002	Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report. <b>2017</b> , 57, 191-197	13
1001	New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. <b>2017</b> , 10, 2513-2526	25
1000	High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab. <b>2018</b> , 15, 3061-3067	8
999	Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology. <b>2017</b> , 23, S13-S20	10
998	Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers. <b>2017</b> , 9, 553-563	11
997	Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma. <b>2017</b> , 10, 763-771	34
996	Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity. <b>2017</b> , 8, 57-66	2
995	PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level. <b>2017</b> , 8, 3251-3260	17
994	AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?. <b>2017</b> , 5, S14	3
993	Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. <b>2017</b> , 9, 207-213	90
992	Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab. <b>2017</b> , 10, 230-234	29
991	Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. <b>2017</b> , 10, 3697-3708	4
990	Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. <b>2017</b> , 8, 48248-48252	65
989	Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <b>2017</b> , 8, 93149-93155	45
988	Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy. <b>2017</b> , 8, 66491-66503	1

987	Targeted therapy for soft tissue sarcomas in adolescents and young adults. <b>2017</b> , 8, 41-55	8
986	Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway. <b>2017</b> , 13,	
985	Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma. <b>2017</b> , 12, e0179000	2
984	Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression. <b>2017</b> , 12, e0181598	25
983	Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. <b>2017</b> , 12, e0183639	2
982	A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. <b>2017</b> , 12, e0186106	12
981	Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma. <b>2017</b> , 12, e0189697	30
980	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. <b>2017</b> , 6, e1344805	97
979	Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer. <b>2017</b> , 12, e0186192	33
978	Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. <b>2017</b> , 103, 405-421	31
977	Clinical Course After Initiation of Nivolumab Therapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer With or Without Pd-L1 Expression. <b>2017</b> , 5, 181-185	0
976	Addressing the challenges of applying precision oncology. <b>2017</b> , 1, 28	19
975	A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer. <b>2017</b> , 17, 683	6
974	Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma. <b>2017</b> , 17, 105	27
973	The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. <b>2017</b> , 16, 149	165
972	Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?. <b>2017</b> , 15, 173	29
971	Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China. <b>2017</b> , 10, 136	33
970	Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. <b>2017</b> , 10, 174	68



969	Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications. <b>2017</b> , 9, 89	23
968	Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report. <b>2017</b> , 11, 183	6
967	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. <b>2017</b> , 5, 66	27
966	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. <b>2017</b> , 5, 93	41
965	A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer. <b>2017</b> , 5, 103	4
964	Immuntherapie thorakaler Tumoren. <b>2017</b> , 20, 21-27	
963	Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. <b>2017</b> , 17, 534	19
962	Immunotherapy in Lung Disease. <b>2017</b> , 76, 36-39	
961	Molekularbiologische Grundlagen der immunonkologischen Therapie. <b>2017</b> , 20, 10-15	1
960	Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP). <b>2017</b> , 56, 2311-2315	18
959	Nivolumab Therapy for Synchronous -Positive Lung Cancer and Gastric Cancer. <b>2017</b> , 10, 361-367	3
958	Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. <b>2017</b> , 12, 403-407	432
957	Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. <b>2017</b> , 6, S8-S20	67
956	Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, efficacy and Resistance. <b>2017</b> , 06,	
955	Recent advances in the management of non-small cell lung cancer. <b>2017</b> , 6, 2110	16
954	High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. <b>2017</b> , 8, 18021-18030	36
953	Live, Learn, Pass It on: A Patient Advocacy Engagement Project on the Lived Experience of Lung Cancer Survivors. <b>2017</b> , 4, 162-168	6
952	Nivolumab Maintenance as Monotherapy after Carboplatin Plus Nab- Paclitaxel for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Study Protocol for Feasibility. <b>2017</b> , 7,	

951	Promoter DNA methylation analysis reveals a combined diagnosis of CpG-based biomarker for prostate cancer. <b>2017</b> , 8, 58199-58209	9
950	Severe Esophagitis and Gastritis from Nivolumab Therapy. <b>2017</b> , 4, e57	49
949	Prognostic and Predictive Value of PD-L1 in Patients with Lung Cancer. <b>2017</b> ,	
948	Checkpoint Inhibitors in Non-small Cell Lung Cancer. <b>2017</b> ,	
947	Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. <b>2017</b> , 8, 61618-61625	8
946	Development and validation of a targeted next generation DNA sequencing panel outperforming whole exome sequencing for the identification of clinically relevant genetic variants. <b>2017</b> , 8, 102033-102045	17
945	An Abscopal Response to Radiation Therapy in a Patient with Metastatic Non-Small Cell Lung Cancer: A Case Report. <b>2017</b> , 09,	5
944	PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study. <b>2017</b> , 8, 98524-98532	37
943	A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma. <b>2017</b> , 1, 83-88	1
942	Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. <b>2017</b> , 8, 8738-8751	87
941	PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients. <b>2017</b> , 9, E384-E386	14
940	Correlation of cancer stem cell markers and immune cell markers in resected non-small cell lung cancer. <b>2017</b> , 8, 3190-3197	5
939	Comparative effectiveness and safety of -paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting. <b>2017</b> , 8, 179-190	6
938	PD1 signal transduction pathways in T cells. <b>2017</b> , 8, 51936-51945	118
937	The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer. <b>2017</b> , 11, 3367-3376	4
936	Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. <b>2017</b> , 11, 1175-1182	10
935	Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients. <b>2017</b> , 10, 2003-2007	5
934	Tumor location impacts immune response in mouse models of colon cancer. <b>2017</b> , 8, 54775-54787	44

933	New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer. <b>2017</b> , 8, 91-99	10
932	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. <b>2017</b> , 23, 1208-1216	39
931	Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. <b>2017</b> , 8, 8910-8920	93
930	Locoregional and systemic therapy for hepatocellular carcinoma. <b>2017</b> , 8, 215-228	46
929	Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence hybridization (FISH) to select the optimal patients for matched therapy?. <b>2017</b> , 8, 100863-100898	11
928	Evidence from a meta-analysis: is nivolumab neurotoxic in cancer patients?. <b>2017</b> , 10, 1335-1344	1
927	Reasons for lack of referral to medical oncology for systemic therapy in stage IV non-small-cell lung cancer: comparison of 2003-2006 with 2010-2011. <b>2017</b> , 24, e486-e493	11
926	Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer. <b>2017</b> , 8, 4075-4082	7
925	PD-1 blockade restores impaired function of ex vivo expanded CD8 T cells and enhances apoptosis in mismatch repair deficient EpCAM <sup>+</sup> PD-L1 cancer cells. <b>2017</b> , 10, 3453-3465	15
924	Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies. <b>2017</b> , 12, e0175679	56
923	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. <b>2017</b> , 8, 41641-41669	13
922	Immunotherapy in Gynecologic Cancers. <b>2017</b> ,	
921	From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. <b>2017</b> , 8, 37-53	40
920	Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. <b>2017</b> , 8, 91779-91794	211
919	Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment. <b>2017</b> , 37, 674-683	12
918	Pembrolizumab in Small-Cell Lung Cancer: In Search of the Best Biomarker. <b>2017</b> , 35, 3794-3795	0
917	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <b>2017</b> , 35, 3484-3515	358
916	Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. <b>2017</b> , 35, 3449-3457	223

915	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <b>2017</b> , 35, 2781-2789	248
914	Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade. <b>2017</b> , 35, 2735-2736	2
913	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). <b>2017</b> , 35, 3924-3933	495
912	Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. <b>2017</b> , 35, 3867-3876	263
911	Triple-Negative Breast Cancer: Current Practice and Future Directions. <b>2017</b> , 13, 301-303	43
910	Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer. <b>2017</b> , 37, 630-639	7
909	Can Prostate Cancer Really Respond to Immunotherapy?. <b>2017</b> , 35, 4-5	6
908	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. <b>2017</b> , 13, 832-837	37
907	Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. <b>2017</b> , 8, 12417-12432	19
906	Established and Novel Prognostic Biomarkers in Multiple Myeloma. <b>2017</b> , 37, 548-560	16
905	The role of novel immunotherapies in non-Hodgkin lymphoma. <b>2017</b> , 6, 93-103	22
904	How Should We Choose the Best Therapy for Elderly Patients With Stage III Non-Small-Cell Lung Cancer?. <b>2017</b> , 35, 2860-2862	
903	Biomarkers for Checkpoint Inhibition. <b>2017</b> , 37, 205-209	8
902	Bending the Curve of Advanced Urothelial Carcinoma. <b>2017</b> , 13, 319-320	
901	Hodgkin lymphoma and PD-1 blockade: an unfinished story. <b>2017</b> , 1, 1-1	4
900	Therapeutic management options for stage III non-small cell lung cancer. <b>2017</b> , 8, 1-20	127
899	EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. <b>2017</b> , 8, 75712-75726	66
898	Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab. <b>2017</b> , 8, 41-54	5

897	Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors. <b>2017</b> , 1, 132-142	2
896	A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC. <b>2017</b> , 9, E292-E294	
895	Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. <b>2017</b> , 9, 655-665	11
894	PD-L1 protein expression in non-small cell lung cancer based on different immunohistochemical antibodies. <b>2017</b> , 9, E470-E473	3
893	Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer. <b>2017</b> , 9, E540-E542	21
892	Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer. <b>2017</b> , 9, 1903-1910	15
891	Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy. <b>2017</b> , 9, 2142-2158	62
890	Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. <b>2017</b> , 9, 2579-2586	32
889	The role of an immune checkpoint score in resected non-small cell lung cancer patients' prognosis. <b>2017</b> , 9, 3480-3482	1
888	KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer. <b>2017</b> , 9, 4187-4190	2
887	Tumor-associated macrophages-additional effectors at anti-PD-1/PD-L1 therapy?. <b>2017</b> , 9, 4197-4200	4
886	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. <b>2017</b> , 6, 373-386	32
885	Biology and clinical significance of circulating tumor cell subpopulations in lung cancer. <b>2017</b> , 6, 431-443	18
884	Immunohistochemistry for predictive biomarkers in non-small cell lung cancer. <b>2017</b> , 6, 570-587	26
883	Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study. <b>2017</b> , 6, S39-S40	4
882	Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. <b>2017</b> , 8, 83986-83994	45
881	Next generation sequencing identifies 'interactome' signatures in relapsed and refractory metastatic colorectal cancer. <b>2017</b> , 8, 20-31	9
880	Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer?. <b>2017</b> , 9, 2771-2773	2

- 879 Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505). **2017**, 9, 3525-3528
- 878 Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed. **2017**, 9, 4821-4824 10
- 877 Reproducibility of PD-L1 assessment in non-small cell lung cancer-know your limits but never stop trying to exceed them. **2017**, 6, S51-S54 7
- 876 Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer. **2017**, 6, S41-S43 2
- 875 Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis.. **2017**, 1, 1-15 31
- 874 Oncogenic pathways as the basis of primary immune ignorance. **2017**, 1, 421-428
- 873 PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. **2017**, 8, 90123-90131 64
- 872 Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. **2017**, 8, 3197-3205 29
- 871 Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. **2018**, 118, 763-769 16
- 870 Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS. **2018**, 1019, 93-102 28
- 869 Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. **2018**, 7, e1440168 25
- 868 Immune-mediated Pericarditis With Pericardial Tamponade During Nivolumab Therapy. **2018**, 41, 329-331 31
- 867 JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers. **2018**, 17, 732-739 14
- 866 Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis. **2018**, 4, 522-528 56
- 865 Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting. **2018**, 19, 360-370 19
- 864 Targeting the microenvironment in solid tumors. **2018**, 65, 22-32 189
- 863 Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC. **2018**, 65, 65-77 25
- 862 Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF $\beta$  enhance the efficacy of cancer immunotherapy. **2018**, 9, 741 138

861	Designing Late-Stage Randomized Clinical Trials with Cancer Immunotherapy: Can We Make It Simpler?. <b>2018</b> , 6, 250-254	3
860	PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. <b>2018</b> , 118, 820-824	117
859	Prognostic Significance of Platelet-Based Inflammatory Indicators in Patients with Gastric Cancer. <b>2018</b> , 42, 2542-2550	18
858	Results and challenges of immune checkpoint inhibitors in colorectal cancer. <b>2018</b> , 18, 561-573	38
857	Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance. <b>2018</b> , 45, 408-415	27
856	Checkpoint inhibitors: 'raising the bar' also in brain metastases from non-small-cell lung cancer?. <b>2018</b> , 10, 403-410	5
855	Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens. <b>2018</b> , 1719, 209-221	34
854	The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?. <b>2018</b> , 13, 291-294	17
853	CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma. <b>2018</b> , 40, 1010428318760420	12
852	Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. <b>2018</b> , 17, 38	253
851	Analysis of middle- and long-term efficacy of thoracoscope-assisted segmental resection of the lung on non-small cell lung cancer in the early stage. <b>2018</b> , 15, 3662-3668	1
850	PD-L1 Expression in Small Cell Lung Cancer. <b>2018</b> , 13, e40-e41	25
849	Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins. <b>2018</b> , 13, e41-e43	2
848	Time is up for PD-L1 testing standardization in lung cancer. <b>2018</b> , 29, 791-792	2
847	Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer. <b>2018</b> , 29, 1320-1324	21
846	Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells. <b>2018</b> ,	8
845	The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses. <b>2018</b> , 7, e1414119	30
844	Promises and challenges of immuno-oncology from a clinical perspective. <b>2018</b> , 48, 101-102	1

843	Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. <b>2018</b> , 23, 410-420	40
842	Immunotherapy in Lung Cancer and the Role of Imaging. <b>2018</b> , 39, 314-321	2
841	Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. <b>2018</b> , 198, 928-940	38
840	Differentially expressed and survival-related proteins of lung adenocarcinoma with bone metastasis. <b>2018</b> , 7, 1081-1092	15
839	Cancer immunotherapy in patients with brain metastases. <b>2018</b> , 67, 703-711	11
838	Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Research Group (TORC) 0809. <b>2018</b> , 41, 1113-1117	3
837	PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma. <b>2018</b> , 67, 805-814	27
836	Breathing New Life Into Hypoxia-Targeted Therapies for Non-Small Cell Lung Cancer. <b>2018</b> , 110,	22
835	Durvalumab in urothelial cancers. <b>2018</b> , 18, 311-318	6
834	Altered Immune-Related Gene Expressions Indicate Oral Cancer Nodal Disease. <b>2018</b> , 97, 709-716	3
833	Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations. <b>2018</b> , 126, 342-352	81
832	Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report. <b>2018</b> , 9, 646-651	3
831	Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers. <b>2018</b> , 14, 337-342	2
830	Computationally-Guided Development of a Stromal Inflammation Histologic Biomarker in Lung Squamous Cell Carcinoma. <b>2018</b> , 8, 3941	7
829	The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. <b>2018</b> , 25, 1814-1827	30
828	Peptidomics. <b>2018</b> ,	3
827	Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <b>2018</b> , 19, 352-359.e1	7
826	Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer. <b>2018</b> , 101, 445-452	6



825	Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma. <b>2018</b> , 118, 62-68	10
824	Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. <b>2018</b> , 119, 112-119	9
823	Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. <b>2018</b> , 119, 14-20	85
822	Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma. <b>2018</b> , 119, 21-24	23
821	Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. <b>2018</b> , 27, 88-94	27
820	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. <b>2018</b> , 41, 284-291	8
819	Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. <b>2018</b> , 233, 6337-6343	65
818	Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. <b>2018</b> , 81, 1105-1109	49
817	Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma. <b>2018</b> , 139, 251-259	12
816	Pitfalls in the radiological response assessment of immunotherapy. <b>2018</b> , 11, 138-143	45
815	The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis. <b>2018</b> , 59, 328-338	11
814	Target Therapy for Esophageal Adenocarcinoma. <b>2018</b> , 1756, 51-65	2
813	Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. <b>2018</b> , 57, 1225-1231	42
812	Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer. <b>2018</b> , 9, 736-744	22
811	Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. <b>2018</b> , 3, e000344	60
810	Relapsed Myasthenia Gravis after Nivolumab Treatment. <b>2018</b> , 57, 1893-1897	25
809	Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy. <b>2018</b> , 94, 153-160	17
808	Towards predictive biomarkers for immunotherapy response in breast cancer patients. <b>2018</b> , 7, BMT05	4

807	The clinical significance of PD-L1 in advanced gastric cancer is dependent on mutations and ATM expression. <b>2018</b> , 7, e1457602		6
806	Precision Targeted Therapy with BLU-667 for -Driven Cancers. <b>2018</b> , 8, 836-849		189
805	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 2078-2092	59.2	2820
804	Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of anti-programmed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice. <b>2018</b> , 10, 1758835918768238		39
803	Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?. <b>2018</b> , 10, 1758835918762094		74
802	PD-L1 expression testing in non-small cell lung cancer. <b>2018</b> , 10, 1758835918763493		90
801	Radiotherapy and checkpoint inhibitors: a winning new combination?. <b>2018</b> , 10, 1758835918768240		58
800	KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer. <b>2018</b> , 19, e489-e501		20
799	The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis. <b>2018</b> , 482, 101-107		26
798	Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. <b>2018</b> , 19, e421-e430		28
797	Lung Cancer: Posttreatment Imaging: Radiation Therapy and Imaging Findings. <b>2018</b> , 56, 471-483		4
796	Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer. <b>2018</b> , 56, 485-495		42
795	Regulatory T cells: a potential target in cancer immunotherapy. <b>2018</b> , 1417, 104-115		123
794	Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung. <b>2018</b> , 117, 1563-1569		15
793	ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. <b>2018</b> , 19, 694-704		201
792	Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer. <b>2018</b> , 36, 726-731		11
791	Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. <b>2018</b> , 120, 62-69		18
790	Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis. <b>2018</b> , 29, 1092-1094		10

789	Clinical assessment of immune-related adverse events. <b>2018</b> , 10, 1758835918764628	74
788	Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges. <b>2018</b> , 10, 1758835918763723	2
787	Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. <b>2018</b> , 66, 114-121	25
786	T Cell Dysfunction in Cancer. <b>2018</b> , 33, 547-562	446
785	Making Sense of Immunotherapy in Lung Cancer: What the Pulmonologist Needs to Know?. <b>2018</b> , 7, 42-48	
784	Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. <b>2018</b> , 95, 68-74	13
783	Anti-Angiogenics: Their Value in Lung Cancer Therapy. <b>2018</b> , 41, 172-180	22
782	Survival benefit from RectroNectin-activated cytokine-induced killer cells combined with chemotherapy in advanced EGFR wild-type lung adenocarcinoma. <b>2018</b> , 10, 501-510	4
781	A single centre phase II trial to assess the immunological activity of TroVax <sup>®</sup> plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial. <b>2018</b> , 7, e1457597	5
780	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <b>2018</b> , 33, 843-852.e4	525
779	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <b>2018</b> , 11, 475-486	52
778	STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. <b>2018</b> , 10, 1758835918763744	17
777	Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management. <b>2018</b> , 20, 44	33
776	Anticancer drug treatment for advanced lung cancer with interstitial lung disease. <b>2018</b> , 56, 307-311	11
775	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer. <b>2018</b> , 23, 1199-1209	25
774	Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly. <b>2018</b> , 51,	7
773	Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma. <b>2018</b> , 142, 1388-1393	3
772	[PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer]. <b>2018</b> , 105, 263-274	10

771	Lung Cancer. <b>2018</b> , 1-21	
770	Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report. <b>2018</b> , 23, 131-135	1
769	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <b>2018</b> , 13, 323-358	241
768	PD-1 /PD-L1 checkpoint in hematological malignancies. <b>2018</b> , 67, 45-55	25
767	PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. <b>2018</b> , 118, 36-40	51
766	Combining chemotherapy with PD-1 blockade in NSCLC. <b>2018</b> , 186, 130-137	56
765	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <b>2018</b> , 7, e1433982	23
764	Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. <b>2018</b> , 29, 959-965	267
763	Central Nervous System Germinomas Express Programmed Death Ligand 1. <b>2018</b> , 77, 312-316	5
762	Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. <b>2018</b> , 129, 130-135	47
761	Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. <b>2018</b> , 31, 965-973	138
760	Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. <b>2018</b> , 126, 253-263	55
759	Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions. <b>2018</b> , 64, 21-29	31
758	Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer. <b>2018</b> , 118, 57-61	31
757	[Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma]. <b>2018</b> , 35, 197-205	3
756	[The biological rationale for immunotherapy in cancer]. <b>2018</b> , 35, 206-222	4
755	Immuno-oncology-101: overview of major concepts and translational perspectives. <b>2018</b> , 52, 1-11	30
754	Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection. <b>2018</b> , 118, 679-697	8

753	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). <b>2018</b> , 118, 654-661	121
752	Temozolomide-associated hypermutation in gliomas. <b>2018</b> , 20, 1300-1309	69
751	Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?. <b>2018</b> , 24, 2239-2240	4
750	Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma. <b>2018</b> , 52, 334-338	3
749	Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153. <b>2018</b> , 81, 679-686	8
748	Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. <b>2018</b> , 23, 634-640	71
747	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. <b>2018</b> , 13, 1-20	23
746	[Dual Immunotherapy in Advanced Non-small Cell Lung Cancer: ?the Progress and Clinical Application].. <b>2022</b> , 25, 102-110	0
745	[Research Progress of Immunotherapy for Non-small Cell Lung Cancer ?with Drive Gene Mutation].. <b>2022</b> , 25, 201-206	
744	Microscale thermophoresis analysis of the molecular interaction between small nuclear ribonucleoprotein polypeptide G and the RING finger domain of RBBP6 towards anti-cancer drug discovery.. <b>2021</b> , 13, 12775-12785	
743	The Evolving Role of PD-L1 Inhibition in Non-Small Cell Lung Cancer: A Review of Durvalumab and Avelumab.. <b>2022</b> , 5, 31-45	
742	Wnt2b and Wnt5a Expressions are Highly Associated with M2 TAMs in Non-Small Cell Lung Cancer.	
741	Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer.. <b>2022</b> , 16, 11795549221092747	0
740	Monitoring of Circulating Exosomal Immuno Checkpoint in Tumor Microenvironment Through Ultrasensitive Aptamer-Functionalized Sers Probes.	
739	Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk.. <b>2022</b> , 11, 670-685	0
738	Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. <b>2022</b> , 15, 533	1
737	Integrative Analysis Constructs an Extracellular Matrix-Associated Gene Signature for the Prediction of Survival and Tumor Immunity in Lung Adenocarcinoma.. <b>2022</b> , 10, 835043	0
736	Vitiligo as durvalumab's immune-related adverse event in lung cancer. <b>2022</b> , 158, 341-342	

- 735 Malignant pleural effusion cell blocks are reliable resources for PD-L1 analysis in advanced lung adenocarcinomas: a concordance study with matched histologic samples.. **2022**,
- 734 Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China.. **2022**, 1 0
- 733 Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer. **2022**, 10, 1047
- 732 Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors. **2022**, 15, 557 0
- 731 Current Status and Prospects of Perioperative Treatment with Immune Checkpoint Inhibitors for Resectable Non-Small Cell Lung Cancer. **2022**, 73, 83-86
- 730 Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer : A single-center observational study. **2022**, 100076
- 729 What Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine.. **2022**, 14, 0
- 728 COMMD2 Upregulation Mediated by an ncRNA Axis Correlates With an Unfavorable Prognosis and Tumor Immune Infiltration in Liver Hepatocellular Carcinoma.. **2022**, 12, 853026 0
- 727 Characteristics and survival of patients with non-small cell lung cancer treated with immune-checkpoint inhibitors in the real-world: experiences from Bergen, Norway.. **2022**, 1-5
- 726 Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.. **2022**, 14, 1
- 725 Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma.. **2022**, 11, 2073010 0
- 724 Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China. **2022**, 13, 0
- 723 Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab.. **2022**, 14, 1641-1651 0
- 722 Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study.. **2022**, 14, 2
- 721 Development of a Clinically Oriented Model to Predict Antitumor Effects after PD-1/PD-L1 Inhibitor Therapy.. **2022**, 2022, 9030782 1
- 720 Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings. **2022**, 0
- 719 Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis of 13 Randomized Controlled Studies. **2022**, 12, 1
- 718 Skin manifestations associated with checkpoint inhibitors. 0

717	Rheumatic immune- and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: a systematic review and meta-analysis.. <b>2022</b> , 105403	
716	Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression.. <b>2022</b> , 13, 874589	1
715	Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis.. <b>2022</b> , 17, e0268288	1
714	Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study.. <b>2022</b> , 22, 179	1
713	Vaccine Therapy in Non-Small Cell Lung Cancer. <b>2022</b> , 10, 740	0
712	Research article: Three-year Follow-up of Neoadjuvant PD-1 inhibitor (Sintilimab) in Non-Small Cell Lung Cancer.. <b>2022</b> ,	1
711	Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.. <b>2022</b> , 168, 50-58	0
710	Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study.. <b>2022</b> , 7, 100468	
709	Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer.. <b>2022</b> , 169, 106-122	1
708	Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.. <b>2022</b> , 12, 876098	0
707	High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.. <b>2022</b> , 10,	2
706	Different Immune Patterns between Primary Tumor and Lymph Node in Non-Small-Cell Lung Cancer: Potential Impact on Neoadjuvant Immunotherapy.. <b>2022</b> , 2022, 8513747	0
705	Advances in biology and novel treatments of SCLC: The four-color problem in uncharted territory.. <b>2022</b> ,	
704	Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT).. <b>2022</b> , 1	
703	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis.. <b>2022</b> , 7, 100474	1
702	Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response.. <b>2022</b> , 170, 17-26	1
701	Analysis of DNA Repair-Related Prognostic Function and Mechanism in Gastric Cancer. <b>2022</b> , 10,	
700	Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).. <b>2022</b> , JCO2102660	10

699	Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors.. <b>2022</b> , 22, 551	0
698	Intra-tumoral angiogenesis correlates with immune features and prognosis in glioma.. <b>2022</b> , 14,	
697	Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma.. <b>2022</b> , 76, 1348-1361	3
696	A novel four-gene signature predicts immunotherapy response of patients with different cancers.. <b>2022</b> , e24494	1
695	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.. <b>2022</b> ,	5
694	Experimental drug treatments for hepatocellular carcinoma: Clinical trial failures 2015 to 2021.. <b>2022</b> ,	
693	CD4 T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy.. <b>2022</b> , 10,	0
692	Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.. <b>2022</b> , 10,	1
691	Association of mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors.. <b>2022</b> , 12, 1766-1783	
690	An analysis report on the application of immune checkpoint inhibitors after liver transplantation. <b>2022</b> , 13, 204062232210993	0
689	Safety and Efficacy of Dostarlimab in Patients with Recurrent/Advanced Non-Small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial. <b>2022</b> ,	3
688	Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis. <b>2022</b> , 2022, 1-14	0
687	The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. <b>2022</b> , 13,	1
686	Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review. <b>2022</b> , 10, 1237	0
685	HLA-I diversity and Tumor Mutational Burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors. <b>2022</b> ,	0
684	Traitement de 1re ligne des CBNPC m̄tastatiques sans addiction oncoghique. <b>2022</b> , 14, 1S52-1S67	
683	Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis. 13,	1
682	Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. 13,	1



681	Simple IHC reveals complex MMR alternations than PCR assays: Validation by LCM and next-generation sequencing.	0
680	Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation TherapyâProof-of-Concept Animal Study. <b>2022</b> , 10, 1173	0
679	Adverse effects under immune checkpoint inhibitors on 18F-FDG PET/CT imaging.	0
678	Rescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer. <b>2022</b> , 14, 2661	1
677	Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC. <b>2022</b> , 14, 2626	1
676	FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. <b>2022</b> ,	0
675	Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis.	0
674	Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer. 12,	0
673	Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review. <b>2022</b> , 20,	1
672	Prosaposin, tumor-secreted protein, promotes pancreatic cancer progression by decreasing tumor-infiltrating lymphocytes.	0
671	An integrated biomarker of PD-L1 expression and intraepithelial CD8 + T cell infiltration was associated with the prognosis of lung cancer patients after intracranial resection of brain metastases.	0
670	Relationship between PatientsâBaseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <b>2022</b> , 2022, 1-14	0
669	Versatile tests for window mean survival time.	0
668	Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced NonâSmall-Cell Lung Cancer Previously Treated With ImmunotherapyâLung-MAP S1800A.	4
667	Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.	1
666	Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. <b>2022</b> , 41,	4
665	Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis. <b>2022</b> , 114445	0
664	Chemo and Immuno-Therapeutic Options for Nonsmall Cell Lung Cancer Lung Cancer. <b>2022</b> , 102, 493-498	

663	Neoadjuvant Immunotherapy in Gastrointestinal Cancers âThe New Standard of Care?. <b>2022,</b>	0
662	Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome. <b>2022, 6,</b>	1
661	Targeted therapies in non-small cell lung cancer and the potential role of AI interventions in cancer treatment.	0
660	Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonâsquamous Non-Small Cell Lung Cancer with Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study. <b>2022, 100355</b>	0
659	Safety evaluation of fixed-dose nivolumab in patients with gastric cancer. <b>2022, 5,</b>	0
658	Landscape of Immunotherapy in Lung Cancer. <b>2022, 719-727</b>	
657	A Meta-Analysis of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer. <b>2022, 12, 4692-4699</b>	
656	PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer. <b>2022, 29, 107327482211075</b>	0
655	Evaluation of Programmed Death Ligand-1 Immunohistochemical Expression and Tumor-Infiltrating Lymphocytes in Different Types of Endometrial Carcinoma. <b>2022, 10, 702-708</b>	
654	Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor. <b>2022, 17, 329-341</b>	1
653	Using surrogate information to improve confirmatory platform trial with sample size re-estimation. 1-20	0
652	A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial.	1
651	MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.	1
650	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. <b>2022, 27, 3798</b>	5
649	Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report. Volume 15, 637-642	0
648	First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.	0
647	Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy.	0
646	First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score â0%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).	1

- 645 Dynamic changes of peripheral NK cells predict outcome in patients with PD-L1 positive Non-Small-Cell Lung Cancer undergoing immune checkpoint inhibitors as second-line therapy. 1-31
- 644 Monitoring of circulating exosomal immune checkpoint in tumor microenvironment through ultrasensitive aptamer-functionalized SERS probes. **2022**, 100177
- 643 Systemtherapie des anaplastischen Schilddrüsenkarzinoms.
- 642 PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. **2022**, 12, 1
- 641 Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. **2022**, 11, 3245 1
- 640 Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target. **2022**, 2
- 639 Resveratrol in cancer treatment with a focus on breast cancer. **2022**, 15,
- 638 Trends in age- and sex-specific lung cancer mortality in Europe and Northern America: Analysis of vital registration data from the WHO Mortality Database between 2000 and 2017. **2022**, 0
- 637 Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC. **2022**, 14, 2898 0
- 636 Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression. 1-13
- 635 Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer. 12, 0
- 634 Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. *thoraxjnl-2020-215614* 0
- 633 Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. **2022**, 14, 2816 0
- 632 Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma.
- 631 iRECIST and atypical patterns of response to immuno-oncology drugs. **2022**, 10, e004849 1
- 630 Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. 15
- 629 Checkpoint inhibitors in non-small cell lung carcinoma therapy for progression to the brain (clinical observation). **2022**, 186-192
- 628 EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment. **2022**, 23, 6489 1

- 627 Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy. **2022**, 172, 98-106 1
- 626 Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer. **2022**, 172, 85-95 2
- 625 Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1. **2022**, 543, 215795 0
- 624 Tumor-Vascular Interactions in Non-Small Cell Lung Cancer. **2022**, 497-508
- 623 The PD-L1/22C3 assay for primary lung cancer is feasible for daily clinical practice irrespective of the diagnostic procedure. **2022**, 34, 64-77
- 622 ICIs-Related Cardiotoxicity in Different Types of Cancer. **2022**, 9, 203 0
- 621 A review of concurrent chemo/radiation, immunotherapy, radiation planning, and biomarkers for locally advanced non-small cell lung cancer and their role in the development of ECOG-ACRIN EA5181. **2022**,
- 620 Whole-Exome Sequencing Uncovers Specific Genetic Variation Difference Based on Different Modes of Drug Resistance in Small Cell Lung Cancer. 12,
- 619 Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?. Publish Ahead of Print,
- 618 Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy. **2022**, 14, 1344 0
- 617 Updates in the Management of Recurrent Glioblastoma Multiforme. 1
- 616 Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology. 13, 1
- 615 Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives. **2022**, 14, 3138
- 614 Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer. **2022**, 10, 1539
- 613 The Cognitive Effects of Radiotherapy for Brain Metastases. 12, 1
- 612 Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. 0
- 611 Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses. **2022**, 15, 786
- 610 Tumor immunotherapy: Mechanisms and clinical applications. **2022**, 1,

609	Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery. 13,	0
608	Multi-modal molecular programs regulate melanoma cell state. <b>2022</b> , 13,	1
607	Prospective assessment using 18F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer. <b>2022</b> , 12,	0
606	Correlation between the Treg/Th17 Index and the Efficacy of PD-1 Monoclonal Antibody in Patients with Advanced Non-Small-Cell Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease. <b>2022</b> , 2022, 1-11	
605	Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy. 12,	3
604	CpG ODN (K3)âlike receptor 9 agonistâinduces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study. <b>2022</b> , 22,	0
603	The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer.	0
602	Treating advanced lung cancer in older veterans with comorbid conditions and frailty. <b>2022</b> ,	
601	Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. <b>2022</b> , 2022, 1-27	0
600	Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab + ipilimumab.	1
599	Clinically-meaningful improvements in therapy for unresectable NSCLC.	0
598	A patient with stage IV adenocarcinoma harboring an EGFR mutation who survived for about 10 years following salvage surgery after molecular targeting drug therapy and chemotherapy. <b>2022</b> , 36, 504-510	
597	Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index.	0
596	Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology.	0
595	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. 1-14	0
594	Primary pulmonary lymphoepithelioma-like carcinoma treated with immunotherapy: A case report and literature review.	
593	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. <b>2022</b> , 10, e004610	1
592	Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors. <b>2022</b> , 14, 3440	

591	Targeting the CD47-SIRP $\beta$ Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils. <b>2022</b> , 14, 3366	0
590	Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. <b>2022</b> , 22,	0
589	Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta-analysis.	0
588	Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China. 12,	0
587	Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists. <b>2022</b> , 29, 4665-4677	0
586	Immunosenescence, inflammaging, and cancer immunotherapy efficacy. 1-12	1
585	Multi-organs perioperative immune-related adverse events and postoperative bronchial anastomotic fistula in a patient receiving neoadjuvant immunotherapy with NSCLC.	0
584	Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma.	1
583	Comprehensive genome profiling in patients with metastatic non-small cell lung cancer: the precision medicine phase 2 randomized SAFIR02-Lung trial.	1
582	Association between Nutritional Status and Treatment Response and Survival in Patients Treated with Immunotherapy for Lung Cancer: A Retrospective French Study. <b>2022</b> , 14, 3439	2
581	Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. <b>2022</b> , 14, 3473	1
580	Exploring immunotherapy in colorectal cancer. <b>2022</b> , 15,	5
579	Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer. <b>2022</b> , e09971	
578	Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. 13,	2
577	Facts and hopes for immunotherapy in renal cell carcinoma.	2
576	Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations.	
575	Mixed response to cancer immunotherapy is driven by intratumor heterogeneity and differential inter-lesion immune infiltration.	0
574	Efficacy in randomised trials: the time matters. <b>2022</b> , 23, 839-840	

- 573 Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations. **2022**, 12, 0
- 572 Applicability analysis of immunotherapy for lung cancer patients based on deep learning. **2022**, 205, 149-156
- 571 Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis. **2022**, 171, 3-8
- 570 Lung Cancer. **2023**, 57-78
- 569 Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer. 0
- 568 The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer. 1
- 567 Comprehensive Analysis of HMCN1 Somatic Mutation in Clear Cell Renal Cell Carcinoma. **2022**, 13, 1282 0
- 566 Effets indésirables rhumatologiques des inhibiteurs de point de contrôle PD-(L)1 dans le cancer du poumon : revue systématique et méta-analyse. **2022**,
- 565 Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases. 12, 0
- 564 Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors. **2022**, 0
- 563 Weighted Log-Rank Test for Clinical Trials with Delayed Treatment Effect Based on a Novel Hazard Function Family. **2022**, 10, 2573 1
- 562 Machine Learning for Computed Tomography Radiomics: Prediction of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma. Publish Ahead of Print,
- 561 Nomogram Prediction Model Analysis of Risk Factors for Conversion to Thoracotomy after Thoracoscopic Resection of Lung Cancer and Prognostic Value of Lung Cancer. **2022**, 2022, 1-10
- 560 Interferon- $\gamma$  predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients. 0
- 559 Anaplastic lymphoma kinase-signal immunity and immunotherapy. 13,
- 558 Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients. 13, 0
- 557 Long non-coding RNA PART1: dual role in cancer. 1
- 556 Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. 13, 0

555	Improving cancer immunotherapy via co-delivering checkpoint blockade and thrombospondin-1 downregulator. <b>2022,</b>	2
554	Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access.	0
553	PD-1T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC.	0
552	Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients.	
551	Positive Correlation of Peripheral CD8+ T Lymphocytes with Immune-Related Adverse Events and Combinational Prognostic Value in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. <b>2022, 14, 3568</b>	0
550	Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study. <b>2022, 2022, 1-10</b>	0
549	Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists's Perspectives. <b>2022, 14, 244-253</b>	
548	The association of efficacy with PD-1/PD-L1 inhibition and tumor mutational burden in advanced nonsmall cell lung cancer: A PRISMA-guided literature review and meta-analysis. <b>2022, 101, e29676</b>	
547	Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres. <b>2022, 12, 1149</b>	0
546	Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. <b>2022, 11, 4373</b>	
545	Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism. <b>2022, 2022, 1-11</b>	
544	Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitors. <b>2022, 22,</b>	1
543	Serum immunoglobulins might be useful predictors of immune-related adverse events after immune checkpoint inhibitor usage in lung cancer.	0
542	Overexpression of 14-3-3 $\beta$ primes disease recurrence, metastasis and resistance to chemotherapy by inducing epithelial-mesenchymal transition in NSCLC. <b>2022, 14, 5838-5854</b>	1
541	Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis.	
540	Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials.	2
539	Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients.	
538	Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer. <b>2022, 12, 1799</b>	2



537	Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. 13,	
536	Progress of immunotherapy in the treatment of pancreatic cancer. 6, 182-191	
535	Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review. 12,	0
534	Grade 3 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study. <b>2022</b> , 14, 3878	1
533	Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a review.	0
532	Recent Advances and Challenges in Cancer Immunotherapy. <b>2022</b> , 14, 3972	3
531	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. 12,	2
530	Fatal pneumonitis associated with immune checkpoint inhibitors: a study based on 128 cohorts with 26,994 participants.	
529	Neutrophils: Musketeers against immunotherapy. 12,	1
528	Nanoscale engagement of immune checkpoint inhibitor PD-L1 in membrane lipid rafts.	
527	Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients.	0
526	AZD4625 is a potent and selective inhibitor of KRAS G12C.	
525	Growth hormone associated with treatment efficacy of immune checkpoint inhibitors in gastric cancer patients. 12,	
524	A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naïve non-small-cell lung cancer: TORG1630.	0
523	Regional Variations in Clinical Trial Outcomes in Oncology. <b>2022</b> , 20, 879-886.e2	0
522	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. 12,	1
521	The gamble between oncolytic virus therapy and IFN. 13,	0
520	Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment. <b>2022</b> , 5, e2227211	0

519	Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients. 12,	
518	Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors. <b>2022</b> , 12, 1229	
517	Comprehensive circular RNA expression profile of lung adenocarcinoma with bone metastasis: Identification of potential biomarkers. 13,	
516	Computational identification of immune-related lncRNA signature for predicting the prognosis and immune landscape of human glioblastoma multiforme. 13,	
515	Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis. <b>2022</b> , 23,	0
514	KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges. <b>2022</b> , 23, 9391	0
513	Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. 12,	0
512	Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy.	0
511	Sex-specific differences in immunogenomic features of response to immune checkpoint blockade. 12,	0
510	Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer. 12,	1
509	Salvage chemotherapy in patients with nonsmall cell lung cancer after prior immunotherapy: a retrospective, real-life experience study. <b>2022</b> , 33, 752-757	
508	Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. 12,	2
507	Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR.	
506	Advances in the Treatment of Postoperative Recurrence of Non-Small Cell Lung Cancer and Their Impact on Survival in Asian Patients. <b>2022</b> ,	0
505	Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors. 13,	1
504	Efficacy and safety of pembrolizumab monotherapy in EGFR-mutant squamous cell lung cancer with PD-L1 over-expression: A case report. <b>2022</b> , 101, e30099	0
503	Core immune cell infiltration signatures identify molecular subtypes and promote precise checkpoint immunotherapy in cutaneous melanoma. 13,	2
502	The epiphany derived from T-cell inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. 13,	

501	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. 12,	0
500	Special issue "The advance of solid tumor research in China" FGFR4 alterations predict efficacy of immune checkpoint inhibitors in non-small cell lung cancer.	
499	Single-cell RNA sequencing reveals the cellular and molecular changes that contribute to the progression of lung adenocarcinoma. 10,	
498	An immunogenic model of KRAS-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations.	0
497	Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%. 12,	1
496	Immunotherapeutic targets in non-small cell lung cancer.	1
495	Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in Nonsmall Cell Lung Cancer: A Multicentre Analysis. 2022, 2022, 1-15	
494	The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials. 2022, 2022, 1-11	
493	EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer. 2022, 14, 3943	2
492	Computational design of PD-L1 small molecule inhibitors for cancer therapy.	2
491	Spatial positioning and matrix programs of cancer-associated fibroblasts promote T cell exclusion in human lung tumors.	2
490	Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer. 2022,	0
489	Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programmed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma. 12,	
488	Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy. 12,	1
487	A real-world analysis of immune checkpoint inhibitor-based therapy after osimertinib treatment in EGFR-mutant non-small cell lung cancer patients. 2022, 100388	0
486	Image-guided intratumoral immunotherapy: Developing a clinically practical technology. 2022, 114505	2
485	Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis. 13,	1
484	Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer. 2022,	0

- 483 Neuerungen in der Systemtherapie des Anaplastischen Schilddrüsenkarzinoms. **2022**, 43, 375-380
- 482 High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade. **2022**, 23, 9124 ○
- 481 Unexpected favorable outcome to sintilimab monotherapy in a relapse pancreatic ductal adenocarcinoma patient with high tumor mutational burden: a case report. Publish Ahead of Print, ○
- 480 PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?. **2022**, 12, 653-671 1
- 479 Targeting KRAS: Crossroads of Signaling and Immune Inhibition. **2022**, 5, 68-78
- 478 Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field. 12, ○
- 477 Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany. **2022**, 172, 65-74 ○
- 476 Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study. **2022**, 174, 113-120 ○
- 475 Development of a Simple and Objective Prognostication Model for Patients with Advanced Solid Malignant Tumors Treated with Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. **2022**, 17, 583-589 ○
- 474 Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: an observational study. **2022**, 22, ○
- 473 Engineered T cell extracellular vesicles displaying PD-1 boost anti-tumor immunity. **2022**, 46, 101606 2
- 472 RNA modification writer expression profiles predict clinical outcomes and guide neoadjuvant immunotherapy in non-small cell lung cancer. **2022**, 84, 104268 ○
- 471 The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. **2022**, 7, 100577 ○
- 470 Effect of neoadjuvant therapy on tumor tissue PD-L1 and VISTA expression levels in non-small-cell lung cancer. **2022**, 14, 1121-1131 ○
- 469 Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. **2022**, 179, 103806 ○
- 468 Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors. **2022**, 173, 101-106 ○
- 467 Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges. **2022**, ○
- 466 Targeted Therapies in Non-small Cell Lung Cancer. **2022**, 1

465	Rational development of molecularly imprinted nanoparticles for blocking PD-1/PD-L1 axis. <b>2022</b> , 13, 10897-10903	2
464	Interdisciplinary Approach in Lung Cancers. <b>2022</b> ,	0
463	Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy. <b>2022</b> , 12, 2091	1
462	Clinical trial design in the era of precision medicine. <b>2022</b> , 14,	3
461	Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer. <b>2022</b> , 29, 6260-6276	0
460	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. <b>2022</b> , 14, 4192	0
459	Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer.	2
458	Photodynamic therapy of lung cancer, where are we?. 13,	1
457	A robust CD8+ T cell-related classifier for predicting the prognosis and efficacy of immunotherapy in stage III lung adenocarcinoma. 13,	0
456	Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases. <b>2022</b> , 10, 2249	0
455	Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor. <b>2022</b> , 18, 3031-3041	0
454	Wnt2b and Wnt5a expression is highly associated with M2 TAMs in non-small cell lung cancer. <b>2022</b> , 48,	1
453	An acetonic extract and secondary metabolites from the endolichenic fungus <i>Nemania</i> sp. EL006872 exhibit immune checkpoint inhibitory activity in lung cancer cell. 13,	0
452	Immune status for monitoring and treatment of bladder cancer. 13,	0
451	Combating pancreatic cancer with ovarian cancer cells.	0
450	Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways. 12,	0
449	Comprehensive analysis of somatic mutator-derived and immune infiltrates related lncRNA signatures of genome instability reveals potential prognostic biomarkers involved in non-small cell lung cancer. 13,	0
448	The Crosstalk between Microbiome and Immunotherapeutics: Myth or Reality. <b>2022</b> , 14, 4641	0

447	Integrin alpha 2 is associated with tumor progression and postoperative recurrence in non-small cell lung cancer.	0
446	Utility of periodic medical questionnaires and examinations for immune-related adverse event screening: A prospective observational study. <b>2022</b> , 17, e0274451	0
445	Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China. Volume 15, 1021-1032	0
444	Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. <b>2022</b> , 7,	2
443	Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study. <b>2022</b> , 22,	1
442	Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer. 13,	1
441	Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. 13,	0
440	Modern Clinical Trials in Radiation Oncology.	0
439	Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction. 13,	0
438	Biomarkers for immune checkpoint inhibitors in solid tumors.	0
437	A Randomized Phase II Trial of Nivolumab versus Nivolumab-Ipilimumab Combination in EGFR-Mutant Non-Small Cell Lung Cancer. <b>2022</b> , 100416	0
436	Phase 1 trial of CV301 in combination with anti-PD -1 therapy in nonsquamous non-small cell lung cancer.	0
435	Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts. 13,	0
434	Safety and efficacy of nivolumab compared with other regimens in patients with melanoma: A network meta-analysis. <b>2022</b> , 101, e29390	0
433	A retrospective study of PD-L1 immunohistochemistry assays for hepatocellular carcinoma. <b>2022</b> ,	0
432	Radiation Recall Pneumonitis: A Rare Syndrome That Should Be Recognized. <b>2022</b> , 14, 4642	1
431	A retrospective study of second-line chemotherapy combined with immunotherapy in advanced non-small cell lung cancer.	0
430	USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. <b>2022</b> , 13,	0

429	Integration of New Systemic Adjuvant Therapies for Non-Small Cell Lung Cancer: Role of the Surgeon. <b>2022</b> ,	0
428	Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis. <b>2022</b> , 54, 2606-2616	0
427	Evaluating the Combined Anticancer Response of Checkpoint Inhibitor Immunotherapy and FAP-Targeted Molecular Radiotherapy in Murine Models of Melanoma and Lung Cancer. <b>2022</b> , 14, 4575	0
426	Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.	0
425	Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.	0
424	PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review. 12,	1
423	Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. <b>2022</b> , 14, 4481	0
422	Current and promising treatment strategies in glioma. <b>2022</b> ,	0
421	Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2,3-dioxygenase 1. <b>2022</b> , 7,	0
420	The Interaction of the IFN $\gamma$ /JAK/STAT1 and JAK/STAT3 Signalling Pathways in EGFR-Mutated Lung Adenocarcinoma Cells. <b>2022</b> , 2022, 1-16	0
419	Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis. <b>2022</b> , 6,	0
418	Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway. <b>2022</b> , 65, 11900-11912	0
417	The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study. 13,	1
416	Thyroid Dysfunction in Non-small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta-Analysis.	0
415	The influence of baseline characteristics on the efficacy of immune checkpoint inhibitors for advanced lung cancer: A systematic review and meta-analysis. 13,	0
414	Neoadjuvant radiation therapy and surgery improves metastasis-free survival over surgery alone in a primary mouse model of soft-tissue sarcoma.	1
413	A Bayesian phase I/ II design to determine subgroup-specific optimal dose for immunotherapy sequentially combined with radiotherapy.	0
412	Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis. <b>2022</b> , 101, e30151	0

411	Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis.	0
410	Outcome of non-small-cell lung cancer with driven mutations treated with anti-PD-(L)1 agents: A systematic review. 030089162211226	0
409	Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab. <b>2022</b> , 14, 4739	1
408	Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. 13,	1
407	Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors. <b>2022</b> , 10, 2211	1
406	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. 13,	0
405	Identification of Immuno-Targeted Combination Therapies Using Explanatory Subgroup Discovery for Cancer Patients with EGFR Wild-Type Gene. <b>2022</b> , 14, 4759	0
404	High Serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. <b>2022</b> ,	0
403	Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial. <b>2022</b> ,	0
402	Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice. <b>2022</b> , 8, e10775	0
401	Probability of Study Success (PrSS) Evaluation Based on Multiple Endpoints in Late Phase Oncology Drug Development. 1-34	0
400	Comparative assessment of early mortality risk upon immunecheckpoint inhibitors alone or in combinations with other agents across solid malignancies: a systematic review and meta-analysis. <b>2022</b> ,	5
399	The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer. <b>2022</b> ,	0
398	Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy. 12,	1
397	Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations.	0
396	SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA.	1
395	Bifidobacterium breve predicts the efficacy of anti-PD -1 immunotherapy combined with chemotherapy in Chinese NSCLC patients.	0
394	Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer. 13,	1



393	Clinical utility of CAR T cell therapy in brain tumors: Lessons learned from the past, current evidence and the future stakes. 1-19	1
392	Efficacy and safety of nivolumab for advanced/recurrent non-small-cell lung cancer: an up-to-date meta-analysis of large-scale phase III randomized controlled trials.	0
391	Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases.	2
390	Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead. <b>2022</b> , 550, 215937	1
389	Risk of developing hypothyroidism with the use of tyrosine kinase inhibitors and immune checkpoint inhibitors. <b>2022</b> , 81, 102265	1
388	NMR-Based Metabolomics to Evaluate Individual Response to Treatments. <b>2022</b> ,	0
387	Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma. <b>2022</b> , 14, 175883592211338	0
386	CRISPR Activation Screening Identifies VGLL3 and EAD1 as a Transcriptional Complex for PD-L1 Expression. <b>2022</b> , 209, 907-915	0
385	Differences and Similarities in the Pattern of Early Metabolic and Morphologic Response after Induction Chemo-Immunotherapy versus Induction Chemotherapy Alone in Locally Advanced Squamous Cell Head and Neck Cancer. <b>2022</b> , 14, 4811	0
384	NEPTUNE: Phase III Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. <b>2022</b> ,	0
383	Nivolumab-induced radiation recall pneumonitis in non-small cell lung cancer patients with thoracic radiation therapy.	0
382	An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non-small cell lung cancer.	0
381	Synthesis and preliminary evaluations of [18F]fluorinated pyridine-2-carboxamide derivatives for targeting PD-L1 in cancer. <b>2022</b> , 23,	0
380	Current status of immunotherapy for non-small cell lung cancer. 13,	1
379	History and Evidence of Immune Checkpoint Inhibitors in the Respiratory Field. <b>2022</b> , 73, 325-331	0
378	Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: a multiplex immunohistochemistry-based single-cell analysis. <b>2022</b> ,	0
377	The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic Driven Non-Small Cell Lung Cancer: A University of California Lung Cancer Consortium Retrospective Study. <b>2022</b> , 100427	0
376	Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre study. 1-8	0

- 375 Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis. **2022**, 50, 301-309 ○
- 374 Outcomes of EGFR tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced EGFR-mutated non-small cell lung cancer. ○
- 373 A Metabolism-Related Gene Prognostic Index for Prediction of Response to Immunotherapy in Lung Adenocarcinoma. **2022**, 23, 12143 ○
- 372 ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production. **2022**, 20, ○
- 371 Biomarqueurs en immunothérapie, signatures moléculaires, radiomique : avons-nous avancé?. **2022**, 14, 2S225-2S232 ○
- 370 Algorithme thérapeutique des cancers bronchiques non ^petites cellules tendus avec mutation de l'EGFR. **2022**, 14, 2S189-2S208 ○
- 369 Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors. 13, ○
- 368 Clinical determinants impacting overall survival of patients with operable brain metastases from non-small cell lung cancer. 12, 1
- 367 Update on Immune Checkpoint Inhibitor Enterocolitis. ○
- 366 Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis. 12, 1
- 365 Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment. 630-642 1
- 364 Seasonal variation in effect of anti-PD -1 initiation on overall survival among patients with advanced melanoma. ○
- 363 Traitements systémiques du cancer bronchique non ^petites cellules chez les sujets âgés. **2022**, 14, 2S327-2S337 ○
- 362 Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?. **2022**, 11, 3280 ○
- 361 Immunoinfiltration-related gene SERPINE1 is a novel biomarker for diagnosis and prognosis of stomach adenocarcinoma discovered via high throughput transcriptome data mining combined with bioinformatics. ○
- 360 Peripheral blood markers predict immunotherapeutic efficacy in patients with advanced non-small cell lung cancer: A multicenter study. 13, ○
- 359 Precision Medicine in Oncology Drug Development. 1-15 ○
- 358 Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor. ○

- 357 PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way. **2022**, 10, e004590 ○
- 356 Using machine learning and RNA to enhance the efficacy of anti-tumor immunotherapy. ○
- 355 Biomarker-Targeted Therapies in Non-small Cell Lung Cancer: Current Status and Perspectives. **2022**, 11, 3200 ○
- 354 Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302. ○
- 353 Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival. 28, 5750-5763 ○
- 352 R animation en oncologie ^ l beure de l immunoth apie. **2022**, 14, 2S287-2S292 ○
- 351 Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study. 13, ○
- 350 PD-L1 expression is not a predictive factor for recurrence in resected non-small cell lung cancer Sub-heading: PD-L1 is not a predictive factor for recurrence. ○
- 349 Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment. Volume 15, 1221-1228 ○
- 348 Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. **2022**, 14, 4933 ○
- 347 Cancer of the Lung. 1-29 ○
- 346 Immune checkpoint inhibitor for different age patients with NSCLC in efficacy: a systematic review and Meta-analysis. ○
- 345 Algorithme th apeutique des CBNPC sans mutation addictive. **2022**, 14, 2S165-2S177 ○
- 344 Squamous cell lung cancer: Current landscape and future therapeutic options. **2022**, ○
- 343 Predictive Factors for the Efficacy of Immune Checkpoint Inhibitors Against Lung Cancer. **2022**, 62, 355-362 ○
- 342 Immune Checkpoint Inhibitors and Tuberculosis Infection in Lung Cancer: A Case Series and Systematic Review With Pooled Analysis. ○
- 341 More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance. ○
- 340 Observational study to predict the efficacy and optimal duration of nivolumab treatment in patients with previously treated advanced or recurrent non-small cell lung cancer. ○

- 339 Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models. **2022**, 1
- 338 Hazard Function Analysis of Recurrence in Patients with Curatively Resected Lung Cancer: Results from the Japanese Lung Cancer Registry in 2010. **2022**, 14, 5119 0
- 337 Analyse de la prise en charge des cancers bronchiques avec mutation du gène de l'EGFR. **2022**, 0
- 336 Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up. 0272989X2211322 0
- 335 Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring. 0
- 334 Liquid Biopsy and Immuno-Oncology for Advanced Nonsmall Cell Lung Cancer. 0
- 333 A promising research direction for colorectal cancer immunotherapy: The regulatory mechanism of CCL5 in colorectal cancer. 12, 0
- 332 Genopathomic profiling identifies signatures for immunotherapy response of lung adenocarcinoma via confounder-aware representation learning. **2022**, 25, 105382 0
- 331 Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report. **2022**, 16, 0
- 330 BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment. **2022**, 23, 13424 0
- 329 Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study. 0
- 328 Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-small Cell Lung Cancer. **2022**, 42, 1956-1974 2
- 327 The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?. 0
- 326 The Influence of the Gut Microbiome in Paediatric Cancer Origin and Treatment. **2022**, 11, 1521 0
- 325 A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma. 13, 0
- 324 Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment. **2022**, 5, e2239874 0
- 323 Radioimmunoconjugates in the age of modern immuno-oncology. **2022**, 310, 121126 1
- 322 The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. **2022**, 310, 121138 0

- 321 Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy. **2022**, 174, 45-49 ○
- 320 RAS: Circuitry and therapeutic targeting. **2023**, 101, 110505 ○
- 319 Development of models for predicting the objective response of immune checkpoint inhibitor therapy in patients with nonsmall-cell lung cancer. **2022**, 8, 27 ○
- 318 Datele din lumea reală - studiiile clinice pentru evaluarea eficacității noilor terapii oncologice. Rolul studiilor observaționale, cu exemplificare în cancerul pulmonar fără celule mici (NSCLC). **2022**, 3, 23 ○
- 317 Dose escalation in the treatment of NSCLC with proton radiotherapy. **2022**, 16, 246-249 ○
- 316 Perspective Chapter: Liposome Mediated Delivery of Immunotherapeutics for Cancer. ○
- 315 NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs. **2022**, 23, 14054 ○
- 314 Prognostic value of 18F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis. 13, ○
- 313 A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus. **2022**, 8, ○
- 312 Characterization of the Immune Microenvironmental Landscape of Lung Squamous Cell Carcinoma with Immune Cell Infiltration. **2022**, 2022, 1-15 ○
- 311 A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice. **2022**, 22, ○
- 310 PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma. 12, ○
- 309 Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection. 1-13 ○
- 308 Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). ○
- 307 Immunoterapia en cãncer de pulmã metastãtico. **2022**, 25, ○
- 306 Predictive performance of PD-L1 tumor proportion score for nivolumab response evaluated using archived specimens in patients with non-small cell lung cancer experiencing a postoperative recurrence. ○
- 305 The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. 13, ○
- 304 Heparin binding epidermal growth factor-like growth factor is a prognostic marker correlated with levels of macrophages infiltrated in lung adenocarcinoma. 12, ○

303	Prognostic Analysis of Spinal Metastasis Secondary to Lung Cancer after Surgeries: A Unicentric, Large-Cohort, Retrospective Study.	0
302	Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer.	0
301	Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. <b>2022,</b>	0
300	Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy. <b>2022,</b>	1
299	Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors. <b>2022,</b> 82, 100969	0
298	Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis. 12,	0
297	Editorial: Impact of immunotherapy in lung cancer. 12,	0
296	Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review. <b>2022,</b> 20,	0
295	Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. <b>2022,</b>	0
294	Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors.	1
293	Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.	0
292	A Bayesian network analysis of immunotherapy and taxane chemotherapy as second- or later-line treatments in non-small cell lung cancer. <b>2022,</b> 101, e31751	0
291	Five-gene Signature for the Prediction of Response to Immune Checkpoint Inhibitors in Patients with Gastric and Urothelial Carcinomas. <b>2022,</b> 154233	0
290	Combining PARP Inhibitor With Immunotherapy-Does the Promise of Preclinical Data Translate to Clinic?.	0
289	Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis. <b>2022,</b> 22,	0
288	Multiple Adverse Events of anti-PD1/PDL1 Therapy: A Case-control Study using a Japanese Prescription-diagnostics Database.	0
287	KCNQ1OT1 sponges miR -34a to promote malignant progression of malignant melanoma via upregulation of the STAT3 / PD-L1 axis.	0
286	The Anti-Programmed Cell Death Protein-1/ Programmed Death-Ligand 1 Me-Too Drugs Tsunami: Hard To Be Millennials Among Baby Boomers. <b>2023,</b> 18, 17-20	0

- 285 Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment. **2023**, 66, 100904 ○
- 284 An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870). **2022**, 14, 175883592211383 ○
- 283 Research Progress of Intestinal Flora in the Treatment of Lung Cancer—Intestinal Flora and Lung Cancer. **2022**, 12, 10933-10941 ○
- 282 Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study. **2023**, 175, 17-26 ○
- 281 Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer. **2023**, 114, 109589 ○
- 280 Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions. **2023**, 206, 107093 ○
- 279 Proteomic analysis of brain metastatic lung adenocarcinoma reveals intertumoral heterogeneity and specific alterations associated with the timing of brain metastases. **2023**, 8, 100741 1
- 278 Stability and Hopf bifurcation of a tumor-immune system interaction model with an immune checkpoint inhibitor. **2023**, 118, 106996 ○
- 277 The Tumor Microenvironment in Hepatocellular Carcinoma. **2022**, ○
- 276 Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer. **2022**, 14, 175883592211440 ○
- 275 Management of Non-Small Cell Lung Cancer: The Era of Immunotherapy. 100-107 ○
- 274 Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis. 12, ○
- 273 Autoimmune pre-disease. **2022**, 103236 1
- 272 Development of Radiomic-Based Model to Predict Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. **2022**, 14, 5931 ○
- 271 An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy. 13, 1
- 270 Positive regulators of T cell proliferation as biomarkers for predicting prognosis and characterizing the immune landscape in lung adenocarcinoma. 13, ○
- 269 Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis. 12, ○
- 268 A Review of the Role of Stereotactic Radiosurgery and Immunotherapy in the Management of Primary Central Nervous System Tumors. **2022**, 10, 2977 ○

- 267 The Role of 8-oxoG Repair Systems in Tumorigenesis and Cancer Therapy. **2022**, 11, 3798 ○
- 266 A tumor vasculature-based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors. **2022**, 8, ○
- 265 Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. **2022**, 24, 269-304 ○
- 264 Radiotherapy of the Primary Disease for Synchronous Metastatic Cancer: A Systematic Review. **2022**, 14, 5929 ○
- 263 Development of therapeutic antibodies for the treatment of diseases. **2022**, 3, 1
- 262 Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer. **2022**, 10, e005581 1
- 261 Assessing the efficacy of immunotherapy in lung squamous carcinoma using artificial intelligence neural network. 13, ○
- 260 Management of Lung Cancer in the Patient with Interstitial Lung Disease. ○
- 259 The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy. Volume 14, 3485-3492 1
- 258 Extremely high infiltration of CD8+PD-L1+ cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report. 12, 1
- 257 Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors. **2022**, 14, 6095 1
- 256 Advanced diagnostic and therapeutic strategies in nanotechnology for lung cancer. 12, 1
- 255 PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study. 13, ○
- 254 Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors? A Systematic Review of the Literature. **2022**, 29, 9428-9436 ○
- 253 Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer. **2022**, 10, e005436 ○
- 252 Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. **2022**, 22, ○
- 251 Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer. **2022**, 14, 6236 ○
- 250 Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution. **2022**, 216043 ○



249	Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab. <b>2022</b> , 23, e552-e561	1
248	Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer. 13,	0
247	TGF- $\beta$ A novel predictor and target for anti-PD-1/PD-L1 therapy. 13,	1
246	A novel plasma proteomic computational model for predicting therapeutic benefit from immune checkpoint inhibitors in non-small cell lung cancer.	0
245	Immune Checkpoint Inhibitor Therapy in Oncology. <b>2022</b> , 4, 579-597	2
244	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- $\beta$ and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.	0
243	Anti-Programmed Cell Death-1 Antibody and Dasatinib Combination Therapy Exhibits Efficacy in Metastatic Colorectal Cancer Mouse Models. <b>2022</b> , 14, 6146	0
242	Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients.	0
241	Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer.	0
240	Protocol for mathematical prediction of patient response and survival to immune checkpoint inhibitor immunotherapy. <b>2022</b> , 3, 101886	0
239	Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor. <b>2022</b> , 7, 100630	0
238	Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial. <b>2022</b> , 10, e004952	0
237	Identifying Patients at Risk of Acute Kidney Injury among Patients Receiving Immune Checkpoint Inhibitors: A Machine Learning Approach. <b>2022</b> , 12, 3157	0
236	Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance. 12,	0
235	Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts. <b>2022</b> , 14, 6148	0
234	Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. <b>2022</b> , 14, 6145	0
233	Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.	0
232	Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. <b>2022</b> , 3,	0

- 231 Cognitive assessment in patients treated by immunotherapy: the prospective Cog-Immuno trial. **2022**, 22, ○
- 230 Two Cases of Subsequent Hepatocellular Carcinoma in ICI-Responsive Non-Small Cell Lung Cancer. **2022**, 100448 ○
- 229 Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis. 13, ○
- 228 Clinical and pharmacoeconomic aspects of the use of prolonged colony-stimulating factors. **2022**, 112-118 ○
- 227 The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study. **2022**, 14, 6184 ○
- 226 Impact of Federal Lung Cancer Screening Policy on the Incidence of Early-stage Lung Cancer. **2022**, ○
- 225 Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma. Volume 16, 4269-4277 ○
- 224 Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites. ○
- 223 Model-based meta-analysis of non-small cell lung cancer with standard-of-care PD -1 inhibitors and chemotherapy for early development decision making. ○
- 222 CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities. **2023**, 11, 165 1
- 221 Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: A Texas study. 12, ○
- 220 Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012â2018. **2023**, 23, ○
- 219 IP-score correlated to endogenous tumour antigen peptide processing: A candidate clinical response score algorithm of immune checkpoint inhibitors therapy in multiple cohorts. 13, ○
- 218 CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFRm Non-Small-Cell Lung Cancer: A Brief Report. **2023**, ○
- 217 Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors. ○
- 216 Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. ○
- 215 Mechanisms of Resistance to Immunotherapies in Cancer. **2023**, 1-30 ○
- 214 Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC. **2023**, 23, ○

213	Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer. <b>2023</b> ,	0
212	A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer. <b>2023</b> , 15, 329	0
211	At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.	1
210	EGFR-Directed Therapy in Lung Cancer. <b>2023</b> ,	0
209	Analyse finale de lâ�tude EVIDENS par r�gion fran�aise : survie et tol�fance en vie r�elle ^3 ans des patients atteints d��n cancer bronchique non ^petites cellules (CBNPC) trait�s par nivolumab. <b>2023</b> , 15, 130	0
208	Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study.	0
207	Molecular characterization based on tumor microenvironment-related signatures for guiding immunotherapy and therapeutic resistance in lung adenocarcinoma. 14,	0
206	Upregulation of complement proteins in lung cancer cells mediates tumor progression. 12,	0
205	Trabectedin and immune checkpoint inhibitors: a blissful combination or another failure in soft tissue sarcomas?.	0
204	Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer. <b>2023</b> , 13, 167	1
203	A case of late and lethal Trousseau’s syndrome induced by pembrolizumab in lung adenocarcinoma.	0
202	Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer. 14,	0
201	Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up�� <b>2023</b> ,	0
200	A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer.	0
199	Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2(+) breast cancer, multiple myeloma, and non-small-cell lung cancer. <b>2022</b> , 34,	1
198	Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients. 1-14	0
197	Wnt/�Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers. <b>2023</b> , 11, 190	0
196	The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer.	0

- 195 Canine oral squamous cell carcinoma as a spontaneous, translational model for radiation and immunology research. 12, ○
- 194 Peripheral and tumor-infiltrating immune cells are correlated with patient outcomes in ovarian cancer. ○
- 193 CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis. 11, e14668 ○
- 192 Targeting regulatory T cells in gastric cancer: Pathogenesis, immunotherapy, and prognosis. **2023**, 158, 114180 ○
- 191 Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors. **2023**, 248, 115064 ○
- 190 Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer. **2023**, 857, 147177 ○
- 189 Anti-Programmed Death Receptor 1 Signalling Immunotherapy as a Part of Curative Intent Strategies for Stages I-III Non-Small Cell Lung Cancer. 109-116 ○
- 188 The outcomes of surgical and non-surgical treatment in patients with spinal metastases of lung cancer: protocol for a prospective cohort study (Preprint). ○
- 187 The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations. 1-15 ○
- 186 The risks of hematological toxicities of nivolumab in cancer patients: A PRISMA-compliant meta-analysis. **2022**, 101, e32393 ○
- 185 Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. ○
- 184 Atypical Response in Metastatic Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: Radiographic Patterns and Clinical Value of Local Therapy. **2023**, 15, 180 ○
- 183 Cancer trials as opportunities to serve and learn from individuals with human immunodeficiency virus. ○
- 182 Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients. **2022**, ○
- 181 Cutaneous Melanoma and Hormones: Focus on Sex Differences and the Testis. **2023**, 24, 599 ○
- 180 Telomere Status of Advanced Non-Small-Cell Lung Cancer Offers a Novel Promising Prognostic and Predictive Biomarker. **2023**, 15, 290 ○
- 179 PD-L1 Expression is not a Predictive Factor for Recurrence in Resected Non-small Cell Lung Cancer. ○
- 178 Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice. **2023**, 30, 462-475 ○

- 177 Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis. ○
- 176 First-line Immunotherapy and Clinically Meaningful Survival Benefits for the Oldest Adults With Lung Cancer. ○
- 175 Use of Programmed Cell Death Protein 1 (PD-1) Inhibitor Therapy in HIV-infected Patients with Advanced Cancer:a single-center study from China. ○
- 174 Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis. ○
- 173 Comprehensive Genomic Profiling in Lung Cancer in the Era of Immunotherapy Approaches: The Role of Molecular Tumour Boards. **2023**, ○
- 172 Gallbladder Cancer: Epigenetic Landscape, Targeted Therapy, and Prospect of Epitherapy. **2023**, 201-235 ○
- 171 Clinical perspectives on serum tumor marker use in predicting prognosis and treatment response in advanced non-small cell lung cancer. **2023**, 1-11 ○
- 170 Tumor immunology. **2023**, 245-452 ○
- 169 Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. **2023**, 11, e005924 ○
- 168 Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors. ○
- 167 Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance. 1-12 ○
- 166 [18F]FDG PET/CT Imaging in Cancer Treatment with Checkpoint Inhibitors. **2023**, 1-40 ○
- 165 Data mining combines bioinformatics discover immunoinfiltration-related gene SERPINE1 as a biomarker for diagnosis and prognosis of stomach adenocarcinoma. **2023**, 13, ○
- 164 Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. 1
- 163 Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting. **2023**, 15, 175883592311528 ○
- 162 Systemic treatment and radiotherapy for patients with non-small cell lung cancer (NSCLC) and HIV infection â systematic review. **2023**, ○
- 161 A signature-based classification of lung adenocarcinoma that stratifies tumor immunity. 12, ○
- 160 The application of patient-derived organoid in the research of lung cancer. ○

- 159 Immunotherapy for older patients with cancer. **2023**, 17, 37-46 ○
- 158 Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. **2023**, 121459 ○
- 157 Upfront and repeated stereotactic radiosurgery in patients with brain metastases from NSCLC. **2023**, ○
- 156 Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer. **2023**, 12, 191 ○
- 155 Lung Immunotherapy in the Elderly with NSCLC â€”the Who, the What, and the When. **2023**, ○
- 154 Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis. 12, ○
- 153 Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis. ○
- 152 Association between PD -1 inhibitor-related adverse events and frailty assessed by frailty index in lung cancer patients. ○
- 151 Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis. **2023**, 18, ○
- 150 Role of nanotechnology in cancer therapies: recent advances, current issues, and approaches. **2023**, 73-95 ○
- 149 Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. **2023**, 22, ○
- 148 Predictive value of 18F-FDG PET/CT for evaluating the response to hypofractionated radiotherapy combined with PD-1 blockade in non-small cell lung cancer. 14, ○
- 147 A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer. **2023**, 23, ○
- 146 PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma. **2023**, 30, ○
- 145 Application of radiomics in lung immuno-oncology. ○
- 144 Combating pancreatic cancer with ovarian cancer cells. **2023**, 15, 2189-2207 ○
- 143 Targeted Therapy for Nonâ€”Small Cell Lung Cancer. **2023**, ○
- 142 Efficacy and safety of combined immunotherapy and stereotactic radiosurgery in NSCLCBM patients and a novel prognostic nomogram: A real-world study. 13, ○

141	Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy. <b>2023</b> , 116, 102542	o
140	Biomarkers of response to immunotherapy in early stage non-small cell lung cancer. <b>2023</b> , 184, 179-196	o
139	The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck. <b>2023</b> , 140, 106363	o
138	Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic. <b>2023</b> , 83, 101004	o
137	Therapeutic efficacy of plant-produced Nivolumab in transgenic C57BL/6-hPD-1 mouse implanted with MC38 colon cancer. <b>2023</b> , 38, e00794	o
136	Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease. <b>2023</b> , 183, 109618	o
135	Biological equivalent dose is associated with radiological toxicity after lung stereotactic ablative radiation therapy. <b>2023</b> , 183, 109552	o
134	Biological functions and therapeutic potential of SHCBP1 in human cancer. <b>2023</b> , 160, 114362	o
133	Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment. <b>2023</b> , 161, 114567	o
132	Current Management of Stage IIIA (N2) Non-Small-Cell Lung Cancer. <b>2023</b> , 33, 189-196	o
131	Qualitative analysis of PD-L1 expression in non-small-cell lung cancer based on chest CT radiomics. <b>2023</b> , 84, 104815	o
130	Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade. <b>2023</b> ,	1
129	Identification and characterization of circular RNAs as novel putative biomarkers to predict anti-PD-1 monotherapy response in metastatic melanoma patients – Knowledge from two independent international studies. <b>2023</b> , 37, 100877	o
128	Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. <b>2023</b> , 4, 113-129.e7	o
127	Immunology and immunotherapy of cholangiocarcinoma.	1
126	Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations. 14,	o
125	Metabolic dialogs between B cells and the tumor microenvironment: Implications for anticancer immunity. <b>2023</b> , 556, 216076	o
124	Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study CPRC 06-2018-2023, 183, 38-48	o

- 123 Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens. ○
- 122 Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report. 14, ○
- 121 Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer. **2023**, 178, 116-122 ○
- 120 Clinicopathological Features of Kidney Injury Related to Immune Checkpoint Inhibitors: A Systematic Review. **2023**, 12, 1349 ○
- 119 Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. **2023**, 14, ○
- 118 The development and implementation of EGFR inhibitors in advanced NSCLC. **2023**, 13-36 ○
- 117 Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland. **2023**, 153, 40039 ○
- 116 CD70 and PD-L1 ( CD274 ) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma. **2023**, 9, 195-207 ○
- 115 Echinacea purpurea-derived homogeneous polysaccharide exerts anti-tumor efficacy via facilitating M1 macrophage polarization. **2023**, 4, 100391 ○
- 114 A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC. **2023**, ○
- 113 Real-world evidence of nivolumab for non-small-cell lung cancer in a developing country. 108155892211478 ○
- 112 Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. **2023**, 11, 508 ○
- 111 TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments. 14, ○
- 110 Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward. Volume 16, 99-108 ○
- 109 Evaluation and management of acute high-grade immunotherapy-related neurotoxicity. **2023**, 9, e13725 ○
- 108 Sample size calculation for the combination test under nonproportional hazards. **2023**, 65, ○
- 107 Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors. **2023**, 21, 133-142.e3 ○
- 106 Progression patterns and site-specific responses in advanced gastric cancer patients treated with nivolumab. ○



105	Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. <b>2023</b> , 30, 2366-2387	0
104	Optimising Cancer Immunotherapy: Challenges and Opportunities. 26-43	0
103	The immunotherapy advancement targeting malignant blastomas in early childhood. 13,	0
102	The Efficacy and Hemorheological Indexes of Ginseng and Its Active Components for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <b>2023</b> , 2023, 1-15	0
101	Heterogeneous expression of predictive biomarkers PD-L1 and TIGIT in non-mucinous lung adenocarcinoma and corresponding lymph node metastasis: A challenge for clinical biomarker testing. <b>2023</b> , 38, 100884	0
100	Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives. <b>2023</b> , 2, 65-78	0
99	NLRC3 is a potential prognostic biomarker that is correlated with immune cell infiltration in lung adenocarcinoma. <b>2023</b> , 13,	0
98	The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients. <b>2023</b> , 28,	0
97	Consistent Stool Metagenomic Biomarkers Associated with the Response To Melanoma Immunotherapy.	1
96	Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. <b>2023</b> , 23,	1
95	Lung cancer immunotherapy: progress, pitfalls, and promises. <b>2023</b> , 22,	0
94	Acquired radioresistance in EMT6 mouse mammary carcinoma cell line is mediated by CTLA-4 and PD-1 through JAK/STAT/PI3K pathway. <b>2023</b> , 13,	0
93	MicroRNA in lung cancer—novel potential way for early diagnosis and therapy.	0
92	Prognostic Model Establishment and Immune Microenvironment Analysis of Lung Adenocarcinoma Based on Ferroptosis-Related Long Noncoding RNAs.	0
91	Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data. 14,	0
90	Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. <b>2023</b> , 8,	0
89	Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study.	0
88	Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL). <b>2023</b> , 4, 100484	0

- 87 MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. **2023**, ○
- 86 Bronchiolitis obliterans syndrome associated with an immune checkpoint inhibitor in a patient with non-small cell lung cancer. **2023**, 42, 101824 ○
- 85 CD169 + sinus macrophages in regional lymph nodes do not predict mismatch-repair status of patients with colorectal cancer. ○
- 84 Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. **2023**, 12, 1833 ○
- 83 Impact of Tobacco, Marijuana, and Alcohol use on Overall Survival in Recurrent Metastatic head and neck Cancer Patients Treated with Immune Checkpoint Inhibitors. ○
- 82 Precision Surgery in NSCLC. **2023**, 15, 1571 ○
- 81 Posttranslational regulation of liver kinase B1 in human cancer. **2023**, 299, 104570 ○
- 80 Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. **2023**, 8, 101160 ○
- 79 CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. **2023**, 14, ○
- 78 Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. **2023**, 184, 103954 ○
- 77 Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. 14, ○
- 76 TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study. **2023**, 4, 100494 ○
- 75 Glycodelin acts as an immunomodulator in NSCLC and is a predictor of poor prognosis for patients receiving immunotherapy. ○
- 74 Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. **2023**, 12, 832 ○
- 73 Mapping cell types in the tumor microenvironment from tissue images via deep learning trained by spatial transcriptomics of lung adenocarcinoma. ○
- 72 Step-down multiple testing procedures for the overall population and partitioning subgroups. 1-11 ○
- 71 MAX transcriptionally enhances PD-L1 to inhibit CD8+ T cell-mediated killing of lung adenocarcinoma cells. **2023**, 386, 104706 ○
- 70 Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients. ○

- 69 Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China. **2023**, 7, 273-284 ○
- 68 Age-period-cohort effect on lung cancer mortality in Spain, 1982â2021. **2023**, 178, 269-276 ○
- 67 Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis. **2023**, 18, ○
- 66 Real-world retrospective study of KRAS mutations in advanced nonsmall cell lung cancer in the era of immunotherapy. ○
- 65 Immune gene patterns and characterization of the tumor immune microenvironment associated with cancer immunotherapy efficacy. **2023**, 9, e14450 ○
- 64 Post-progression survival in advanced non-small cell lung cancer treated with anti-PD-1/PDL-1 monotherapy: progression after durable clinical benefit versus primary resistance. ○
- 63 Anti-PD-(L)1 therapy of non-small cell lung cancerâA summary of clinical trials and current progresses. **2023**, 9, e14566 ○
- 62 Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 â50% in Patients Treated in Quebecâ University Teaching Hospitals (DALP-First Study). **2023**, 30, 3251-3262 ○
- 61 Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions. ○
- 60 Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test. **2023**, 36, 100159 ○
- 59 Expression and Clinical Significance of PD-L1 and PD-1 in Thymic Carcinoma. **2023**, 13, 3702-3708 ○
- 58 Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study. 13, ○
- 57 Nanomedicine in Lung Cancer Immunotherapy. 11, ○
- 56 Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival. ○
- 55 Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. **2023**, 15, 175883592311614 ○
- 54 Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors. ○
- 53 Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. **2023**, 16, ○
- 52 Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice. **2023**, 12, 2409 ○

- 51 Examination of the Functional Relationship between PD-L1 DNA Methylation and mRNA Expression in Non-Small-Cell Lung Cancer. **2023**, 15, 1909 ○
- 50 Global trends in the health economics field of PD-1/PD-L1 inhibitors: A bibliometric and visualized study. 14, ○
- 49 Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC. 13, ○
- 48 Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT). **2023**, 8, 101192 ○
- 47 Prioritizing exhausted T cell marker genes highlights immune subtypes in pan-cancer. **2023**, 26, 106484 ○
- 46 Onionin A inhibits small-cell lung cancer proliferation through suppressing STAT3 activation induced by macrophages-derived IL-6 and cell-cell interaction with tumor-associated macrophage. **2023**, 36, 1068-1080 ○
- 45 Application status and future prospects of the PDX model in lung cancer. 13, ○
- 44 Patterns of Response to Immune Oncology Drugs: How Relevant Are They in SCCHN?. **2023**, 217-228 ○
- 43 The Value of Comprehensive Molecular Profiling in Early Stage Lung Cancer. **2023**, 18, 393-395 ○
- 42 Date de tip real world privind utilizarea nivolumabului în cancerul pulmonar nonmicrocelular avansat încolo de linia a doua. Experiența noastră în România imediat după ambursarea imunoterapiei prin sistemul național de sănătate. **2023**, 1, 32 ○
- 41 Immunotherapy efficacy predictive tool for lung adenocarcinoma based on neural network. 14, ○
- 40 Oncogenic epidermal growth factor receptor signal-induced histone deacetylation suppresses chemokine gene expression in human lung adenocarcinoma. **2023**, 13, ○
- 39 Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms. **2023**, 23, ○
- 38 Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer. ○
- 37 Feasibility and safety of shortened hypofractionated high-dose palliative lung radiotherapy – A retrospective planning study. **2023**, 108, 102559 ○
- 36 Randomized Clinical Trials: Pitfalls in Design, Analysis, Presentation, and Interpretation. **2023**, ○
- 35 Advancing Cancer Immunotherapy Through Integrating Molecular and Computational Approaches. **2023**, 1-22 ○
- 34 Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report. ○

- 33 Vimentin expression correlates with immune-checkpoint inhibitor efficacy in non-small cell lung cancer. ○
- 32 Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. ○
- 31 Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. **2023**, 11, 1073 ○
- 30 Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. **2023**, 30, 174-194 ○
- 29 Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. ○
- 28 Correlation of LOXL2 expression in non-small cell lung cancer with immunotherapy and clinical prognosis. ○
- 27 Gastrointestinal and Hepatobiliary Immune-related Adverse Events: A Histopathologic Review. **2023**, 30, 230-240 ○
- 26 Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence. **2023**, 15, 2278 ○
- 25 Novel strategies for cancer immunotherapy: counter-immunoediting therapy. **2023**, 16, ○
- 24 Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials. 13, ○
- 23 Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer. **2023**, 15, 1252 ○
- 22 Heterogeneity in the immune microenvironment of bone metastasis in driver-positive non-small cell lung cancer. ○
- 21 In vivo CRISPR screen identifies KRAS-induced COX-2 as a driver of immune evasion and immunotherapy resistance in lung cancer. ○
- 20 Immunotherapy in Lung Cancer: Current Landscape and Analysis of Biomarkers. **2023**, 13, 37-43 ○
- 19 PD-L1 and PD-L2 Immune Checkpoint Protein Induction by Type III Interferon in Non-Small Cell Lung Cancer Cells. **2023**, 152389 ○
- 18 Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer. **2023**, 11, e005539 ○
- 17 Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring. **2023**, 18, ○
- 16 The Value of Peripheral Blood Index in the Evaluation of Curative Effect of Advanced Non-Small Cell Lung Cancer. **2023**, 13, 5979-5988 ○

- 15 Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies; a rapidly evolving strategy. **2023**, 154473 ○
- 14 Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer. **2023**, 24, 7577 ○
- 13 Regulation of early diagnosis and prognostic markers of lung adenocarcinoma in immunity and hypoxia. **2023**, 13, ○
- 12 Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances. **2023**, 154470 ○
- 11 Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis. ○
- 10 Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type. **2023**, 24, 7592 ○
- 9 Chemotherapy. **2023**, 7-159 ○
- 8 Tumor-infiltrating CD36+CD8+T cells determine exhausted tumor microenvironment and correlate with inferior response to chemotherapy in non-small cell lung cancer. **2023**, 23, ○
- 7 Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial. ○
- 6 Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy. ○
- 5 Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients. 13, ○
- 4 A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitors in solid tumors: The OTHERS study. **2023**, 187, 104016 ○
- 3 Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. ○
- 2 Immune Checkpoint Blockade Therapy for Breast Cancer: Lessons from Epithelial-Mesenchymal Transition. ○
- 1 PDE4D/cAMP/IL-23 axis determines the immunotherapy efficacy of lung adenocarcinoma via activating the IL-9 autocrine loop of cytotoxic T lymphocytes. **2023**, 565, 216224 ○